{"parse":{"title":"Prescription drug prices in the United States","pageid":350292,"revid":859315823,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-content ambox-lead_too_short\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><a href=\"/wiki/File:Wiki_letter_w.svg\" class=\"image\"><img alt=\"Wiki letter w.svg\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/6/6c/Wiki_letter_w.svg/40px-Wiki_letter_w.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/6/6c/Wiki_letter_w.svg/60px-Wiki_letter_w.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/6c/Wiki_letter_w.svg/80px-Wiki_letter_w.svg.png 2x\" data-file-width=\"44\" data-file-height=\"44\" /></a></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article's <b><a href=\"/wiki/Wikipedia:Manual_of_Style/Lead_section\" title=\"Wikipedia:Manual of Style/Lead section\">lead section</a> does not adequately <a href=\"/wiki/Wikipedia:Summary_style\" title=\"Wikipedia:Summary style\">summarize</a> key points of its contents</b>.<span class=\"hide-when-compact\"> Please consider expanding the lead to <a href=\"/wiki/Wikipedia:Manual_of_Style/Lead_section#Provide_an_accessible_overview\" title=\"Wikipedia:Manual of Style/Lead section\">provide an accessible overview</a> of all important aspects of the article. Please discuss this issue on the article's <a href=\"/wiki/Talk:Prescription_drug_prices_in_the_United_States\" title=\"Talk:Prescription drug prices in the United States\">talk page</a>.</span>  <small><i>(March 2016)</i></small></div></td></tr></tbody></table>\n<p><b>Prescription drug prices in the United States</b> have been among the highest in the world. The high <a href=\"/wiki/Prescription_costs\" title=\"Prescription costs\">cost of prescription drugs</a> became a major topic of discussion in the new millennium, leading up to the <a href=\"/wiki/U.S._health_care_reform\" class=\"mw-redirect\" title=\"U.S. health care reform\">U.S. health care reform</a> debate of 2009, and received renewed attention in 2015. High <a href=\"/wiki/Prescription_drug_prices\" class=\"mw-redirect\" title=\"Prescription drug prices\">prescription drug prices</a> have been attributed to <a href=\"/wiki/Government-granted_monopoly\" title=\"Government-granted monopoly\">government-granted monopolies</a> to manufacturers and organizations lacking ability to negotiate prices.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Drug_expenditures\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Drug expenditures</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Effects\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Effects</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Prescriptions_from_other_countries\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Prescriptions from other countries</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Prescription_non-compliance\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Prescription non-compliance</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#Affordable_Care_Act\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">Affordable Care Act</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Health_Effects\"><span class=\"tocnumber\">3.4</span> <span class=\"toctext\">Health Effects</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Reasons_for_high_prices\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Reasons for high prices</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Variability_and_non-transparency\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Variability and non-transparency</span></a></li>\n<li class=\"toclevel-2 tocsection-10\"><a href=\"#Market_exclusivity\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">Market exclusivity</span></a></li>\n<li class=\"toclevel-2 tocsection-11\"><a href=\"#Drug_company_profits\"><span class=\"tocnumber\">4.3</span> <span class=\"toctext\">Drug company profits</span></a></li>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#Pharmacy_benefit_managers\"><span class=\"tocnumber\">4.4</span> <span class=\"toctext\">Pharmacy benefit managers</span></a></li>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#Drug_rebates\"><span class=\"tocnumber\">4.5</span> <span class=\"toctext\">Drug rebates</span></a></li>\n<li class=\"toclevel-2 tocsection-14\"><a href=\"#Orphan_drugs\"><span class=\"tocnumber\">4.6</span> <span class=\"toctext\">Orphan drugs</span></a></li>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#FDA_backlog_in_generic_drug_application_review\"><span class=\"tocnumber\">4.7</span> <span class=\"toctext\">FDA backlog in generic drug application review</span></a></li>\n<li class=\"toclevel-2 tocsection-16\"><a href=\"#Research_and_development\"><span class=\"tocnumber\">4.8</span> <span class=\"toctext\">Research and development</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-17\"><a href=\"#Solutions\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Solutions</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-18\"><a href=\"#Discounts\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">Discounts</span></a></li>\n<li class=\"toclevel-2 tocsection-19\"><a href=\"#Drug_Coupons\"><span class=\"tocnumber\">5.2</span> <span class=\"toctext\">Drug Coupons</span></a></li>\n<li class=\"toclevel-2 tocsection-20\"><a href=\"#Generics_versus_brand-name_products\"><span class=\"tocnumber\">5.3</span> <span class=\"toctext\">Generics versus brand-name products</span></a></li>\n<li class=\"toclevel-2 tocsection-21\"><a href=\"#Value-based_prices\"><span class=\"tocnumber\">5.4</span> <span class=\"toctext\">Value-based prices</span></a></li>\n<li class=\"toclevel-2 tocsection-22\"><a href=\"#Policy_makers\"><span class=\"tocnumber\">5.5</span> <span class=\"toctext\">Policy makers</span></a></li>\n<li class=\"toclevel-2 tocsection-23\"><a href=\"#New_legislation\"><span class=\"tocnumber\">5.6</span> <span class=\"toctext\">New legislation</span></a></li>\n<li class=\"toclevel-2 tocsection-24\"><a href=\"#Canada&#39;s_model\"><span class=\"tocnumber\">5.7</span> <span class=\"toctext\">Canada's model</span></a></li>\n<li class=\"toclevel-2 tocsection-25\"><a href=\"#Healthcare_providers\"><span class=\"tocnumber\">5.8</span> <span class=\"toctext\">Healthcare providers</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-26\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-27\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-28\"><a href=\"#Further_reading\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Further reading</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=1\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/Pharmaceutical_drugs\" class=\"mw-redirect\" title=\"Pharmaceutical drugs\">Pharmaceutical drugs</a> are the only major health care service in which the producer is able to set prices with little constraint, according to <a href=\"/wiki/Peter_Bach\" title=\"Peter Bach\">Peter Bach</a> from the Health Outcomes Research Group, <a href=\"/wiki/Memorial_Sloan_Kettering_Cancer_Center\" title=\"Memorial Sloan Kettering Cancer Center\">Memorial Sloan Kettering Cancer Center</a>, New York and Steven Pearson from the Institute for Clinical and Economic Review, Boston.<sup id=\"cite_ref-JAMA2_2-0\" class=\"reference\"><a href=\"#cite_note-JAMA2-2\">&#91;2&#93;</a></sup> As of  2004<sup class=\"plainlinks noexcerpt noprint asof-tag update\" style=\"display:none;\"><a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit\">&#91;update&#93;</a></sup>, prices of brand name drugs were significantly higher in the United States (US) than in Canada, India, the UK and other countries, nearly all of which have <a href=\"/wiki/Price_controls\" title=\"Price controls\">price controls</a>, while prices for <a href=\"/wiki/Generic_drug\" title=\"Generic drug\">generic drugs</a> tended to be higher in Canada.<sup id=\"cite_ref-morgan_3-0\" class=\"reference\"><a href=\"#cite_note-morgan-3\">&#91;3&#93;</a></sup>\n</p><p>One of the reasons drug prices are much higher in the US compared to other industrialized countries is that the U.S. lacks a <a href=\"/wiki/Publicly_funded_health_care\" title=\"Publicly funded health care\">national healthcare system</a> that directly negotiates with the pharmaceutical industry. Rather, most negotiations occur between pharmaceutical companies and private insurers or vendors.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>\n</p><p>In 2003, a Republican-majority Congress created <a href=\"/wiki/Medicare_Part_D\" title=\"Medicare Part D\">Medicare Part D</a>, which prevented Medicare the country's largest single-payer health care system from negotiating drug prices. In effect, drug manufacturers in the US were allowed to set their own prices resulting in the unregulated pricing variation for prescription drugs.<sup id=\"cite_ref-:5_5-0\" class=\"reference\"><a href=\"#cite_note-:5-5\">&#91;5&#93;</a></sup> \nHowever, the government does employ drug pricing strategies for other smaller government health programs like the <a href=\"/wiki/Veterans_Health_Administration\" title=\"Veterans Health Administration\">Veterans Health Administration</a>, the <a href=\"/wiki/United_States_Department_of_Defense\" title=\"United States Department of Defense\">Department of Defense</a>, the <a href=\"/wiki/340B_Drug_Pricing_Program\" title=\"340B Drug Pricing Program\">340B Drug Pricing Program</a> (1992), and <a href=\"/wiki/Medicaid\" title=\"Medicaid\">Medicaid</a>.<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>\n</p><p>In 2005, the <a href=\"/wiki/Government_Accountability_Office\" title=\"Government Accountability Office\">Government Accountability Office</a> (GAO) examined the change in US drug <a href=\"/wiki/Retail_price\" class=\"mw-redirect\" title=\"Retail price\">retail prices</a> from January 2000 through December 2004 and found the average <a href=\"/wiki/Usual,_customary_and_reasonable\" title=\"Usual, customary and reasonable\">usual and customary</a> (U&amp;C) prices for a 30-day supply of 96 drugs frequently used by people enrolled in <a href=\"/wiki/BlueCross_BlueShield\" class=\"mw-redirect\" title=\"BlueCross BlueShield\">BlueCross BlueShield</a> Federal Employee Programs had increased 24.5%. The average U&amp;C prices for brand prescription drugs increased three times as much as the average for generic drug.<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p><p>In 2007, the <a href=\"/wiki/AARP\" title=\"AARP\">AARP</a> published a series of studies showing that <a href=\"/wiki/Prescription_drug_prices\" class=\"mw-redirect\" title=\"Prescription drug prices\">prescription drug prices</a> have been rising significantly faster than general inflation.<sup id=\"cite_ref-8\" class=\"reference\"><a href=\"#cite_note-8\">&#91;8&#93;</a></sup> \nThe <a href=\"/wiki/American_Enterprise_Institute\" title=\"American Enterprise Institute\">American Enterprise Institute</a>, a conservative <a href=\"/wiki/Think_tank\" title=\"Think tank\">think tank</a>, criticized the methodology as overstating drug price inflation.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup>\n</p><p>A December 2015 NYT editorial stated that \"drug prices have been pushed to astronomical heights for no reason other than the desire of drug makers to maximize profits\", pointing in particular to strategies by <a href=\"/wiki/Turing_Pharmaceuticals\" title=\"Turing Pharmaceuticals\">Turing Pharmaceuticals</a> and <a href=\"/wiki/Valeant_Pharmaceuticals\" class=\"mw-redirect\" title=\"Valeant Pharmaceuticals\">Valeant Pharmaceuticals</a> for rights to make and sell generic drugs which had administrative exclusivity<sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Please_clarify\" title=\"Wikipedia:Please clarify\"><span title=\"The text near this tag needs further explanation. (July 2017)\">further explanation needed</span></a></i>&#93;</sup> and then raise the prices dramatically, which were widely condemned in- and outside the pharmaceutical industry.<sup id=\"cite_ref-NYT-20151219_10-0\" class=\"reference\"><a href=\"#cite_note-NYT-20151219-10\">&#91;10&#93;</a></sup> In response, the Department of Health and Human Services and both houses of Congress held a public meeting and hearings respectively to investigate <a href=\"/wiki/Price_gouging\" title=\"Price gouging\">price gouging</a>.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup> In April 2017, Maryland became the first state to grant the state attorney general the authority to sue drug companies for dramatically increasing drug prices.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Drug_expenditures\">Drug expenditures</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=2\" title=\"Edit section: Drug expenditures\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Spending on pharmaceuticals can be defined as <a href=\"/wiki/Expenditure\" class=\"mw-redirect\" title=\"Expenditure\">expenditure</a> on prescriptions medicines and over-the-counter products, excluding pharmaceuticals consumed in hospitals,<sup id=\"cite_ref-oecd_13-0\" class=\"reference\"><a href=\"#cite_note-oecd-13\">&#91;13&#93;</a></sup> This has been mentioned together with drug price, but is not the same.\n</p><p>In 1960, spending on pharmaceuticals accounted for 11.5% of U.S. national healthcare expenses, gradually falling to a low of 5.5% in 1980, before rising back up to 10.4% in 2000 and between 2000 and 2013, it ranged between 10% and 12%.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup>\n</p><p>In 2010, prescription drug expenses were 10% of the $2.6 trillion of total health care spending in the US, and its third largest portion after hospital spending and physician and clinical services.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>\n</p><p>As of 2013, US \"pharmaceutical spending,\" excluding hospital pharmaceutical spending, was $1,034 per capita in the <a href=\"/wiki/OECD\" title=\"OECD\">OECD</a>'s international comparisons.<sup id=\"cite_ref-oecd_13-1\" class=\"reference\"><a href=\"#cite_note-oecd-13\">&#91;13&#93;</a></sup> In 2006, data from the <a href=\"/wiki/Medical_Expenditure_Panel_Survey\" title=\"Medical Expenditure Panel Survey\">Medical Expenditure Panel Survey</a> was analyzed to determine the costs of healthcare for American households. It showed that 19.1% of Americans were considered to have a financial burden due to healthcare spending as they spent more than 10% of their income on it.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup>\n</p><p>In 2003, data from the <a href=\"/wiki/Medical_Expenditure_Panel_Survey\" title=\"Medical Expenditure Panel Survey\">Medical Expenditure Panel Survey</a> showed that only 9.5% of Americans with <a href=\"/wiki/Medicare_(United_States)\" title=\"Medicare (United States)\">Medicare</a> coverage had no prescription drug expenses, while 61.6% had prescription drug expenses up to $2,083, and 28.9% of those on Medicare had expenses higher than $2,084.<sup id=\"cite_ref-:1_17-0\" class=\"reference\"><a href=\"#cite_note-:1-17\">&#91;17&#93;</a></sup> low income families tended to have higher prescription drug expenses during the year: 18.9% of poor households paid more than $4,724 compared to 13.2% and 12.5% who had prescription drug expenses between $2,084-$4,723 and $1\u20132,083, respectively.<sup id=\"cite_ref-:1_17-1\" class=\"reference\"><a href=\"#cite_note-:1-17\">&#91;17&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Effects\">Effects</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=3\" title=\"Edit section: Effects\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In 2006, data from the <a href=\"/wiki/Medical_Expenditure_Panel_Survey\" title=\"Medical Expenditure Panel Survey\">Medical Expenditure Panel Survey</a> was analyzed to determine the costs of healthcare for American households. It showed that 19.1% of Americans spent more than 10% of their income on healthcare related expenses. Those Americans were considered to have a financial burden due to their healthcare spending.<sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup> The high cost of prescription drugs has forced many Americans to use cost-cutting measures and has also led to reformed healthcare legislation.\n</p>\n<h3><span class=\"mw-headline\" id=\"Prescriptions_from_other_countries\">Prescriptions from other countries</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=4\" title=\"Edit section: Prescriptions from other countries\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <i>Washington Post</i> wrote in 2003 that \"<a href=\"/wiki/U.S._Customs_and_Border_Protection\" title=\"U.S. Customs and Border Protection\">U.S. Customs</a> estimated 10 million U.S. citizens brought in medications at land borders each year. An additional 2 million packages of pharmaceuticals arrive annually by international mail from Thailand, India, South Africa and other points\".<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup> Prescription drugs also entered the country in large quantities through Canada because of the price differential of prescription drugs in the two countries. In 2004, it was estimated that Americans purchased more than $1 billion in US dollars in brand-name drugs per year from Canadian pharmacies to save money.<sup id=\"cite_ref-20\" class=\"reference\"><a href=\"#cite_note-20\">&#91;20&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Prescription_non-compliance\">Prescription non-compliance</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=5\" title=\"Edit section: Prescription non-compliance\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Another common way that people saved money, was to skip or reduce dosages or fail to fill a prescription entirely due to cost restrictions. A quarter of Americans taking prescription drugs said in June 2015, they had not filled a prescription in the past 12 months due to cost, and 18 percent reported they \"cut pills in half or skipped doses\" according to a <a href=\"/wiki/Kaiser_Family_Foundation\" title=\"Kaiser Family Foundation\">Kaiser Family Foundation</a> survey.<sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup> Similar studies, done ten years prior, found numbers very similar to the 2015 numbers from the Kasier Family Foundation survey. In 2007, it was estimated that 23.1% of Americans (51 million) had not adhered to their prescription instructions due to the cost of prescription drugs. This is compared to only 8% of Canadians who skipped doses or failed to fill a prescription in the same year because of the cost of prescription medications.<sup id=\"cite_ref-:2_22-0\" class=\"reference\"><a href=\"#cite_note-:2-22\">&#91;22&#93;</a></sup> The number of Americans who reported cost-related non-adherence to their prescriptions was more than double the number of Canadians. The factors that contributed to whether or not a person was more likely to not follow their prescribed medication instructions were age, the number of checkups with a physician, ongoing health problems, income, and insurance coverage.<sup id=\"cite_ref-:2_22-1\" class=\"reference\"><a href=\"#cite_note-:2-22\">&#91;22&#93;</a></sup><sup id=\"cite_ref-:3_23-0\" class=\"reference\"><a href=\"#cite_note-:3-23\">&#91;23&#93;</a></sup>  For example, adults between the ages of 18-35 were more likely to skip doses or fail to fill a prescription than those 75 years of age or older.<sup id=\"cite_ref-:3_23-1\" class=\"reference\"><a href=\"#cite_note-:3-23\">&#91;23&#93;</a></sup> Those with fewer visits to a physician and those with chronic illnesses or disabilities were also more likely to report noncompliance. The reason for those with ongoing illness or disabilities to skip doses is likely due to the increased complexity and the higher prices of the drugs needed.<sup id=\"cite_ref-:3_23-2\" class=\"reference\"><a href=\"#cite_note-:3-23\">&#91;23&#93;</a></sup> Income and insurance coverage were also major factors determining whether or not a patient would take their medication in the correct doses for the correct duration of time. Those who lacked insurance coverage or were in low-income brackets had very high rates of non-compliance with their medication, even though the United States has drug coverage policies for those with low incomes.<sup id=\"cite_ref-:3_23-3\" class=\"reference\"><a href=\"#cite_note-:3-23\">&#91;23&#93;</a></sup> Those whose healthcare spending is more than 10% of their income and causes a financial burden to the patient, are considered uninsured, whether they actually have health insurance or not.<sup id=\"cite_ref-:2_22-2\" class=\"reference\"><a href=\"#cite_note-:2-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Affordable_Care_Act\">Affordable Care Act</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=6\" title=\"Edit section: Affordable Care Act\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2010, the <a href=\"/wiki/Patient_Protection_and_Affordable_Care_Act\" title=\"Patient Protection and Affordable Care Act\">Patient Protection and Affordable Care Act</a>, commonly known as Obamacare or the Affordable Care Act, was created. The goal was to increase the number of people who had healthcare in the United States and reduce the impact that individual healthcare spending had on households, especially since many Americans had lost their health insurance coverage in the <a href=\"/wiki/Great_Recession\" title=\"Great Recession\">Great Recession</a>. Of its many provisions, two aim to reduce the burden of prescription drugs, both relating to the <a href=\"/wiki/Medicare_Part_D_coverage_gap\" title=\"Medicare Part D coverage gap\">Medicare Part D coverage gap</a>. Under 2016 Medicare coverage, people paid the deductible until they reached the limit of $3,310. They then entered the coverage gap where they paid about half the total cost for the drug. Once the yearly <a href=\"/wiki/Out-of-pocket_expenses\" class=\"mw-redirect\" title=\"Out-of-pocket expenses\">out-of-pocket expenses</a> reached $4,850, catastrophic coverage phase begins and the person only pays a very small amount for continued medication.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> In 2010, the first provision enacted immediately, was a one-year, $250 rebate to those people in the coverage gap to help pay for their medication. The second provision, enacted in January 2011, created a 50% discount on <a href=\"/wiki/Brand-name\" class=\"mw-redirect\" title=\"Brand-name\">brand-name</a> prescription drugs for seniors within the coverage gap. Subsidies were to be provided until 2020, when the coverage gap was estimated be closed.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup><sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers\" title=\"Wikipedia:Manual of Style/Dates and numbers\"><span title=\"Need the year this event took place (July 2018)\">year&#160;needed</span></a></i>&#93;</sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Health_Effects\">Health Effects</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=7\" title=\"Edit section: Health Effects\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>High drug prices create a barrier to appropriate treatment for many people who cannot afford their prescriptions; a 2015 survey found that 8% of Americans did not take their medications as prescribed to save money.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> This especially impacts the uninsured and those with insurance plans that do not cover their prescriptions or have high cost-sharing fees.\n</p><p>One way to examine the potential impact of high drug prices on health outcomes is to look at the effects of having prescription drug insurance and subsequent hospitalizations. Studies have linked obtaining prescription insurance plans to fewer hospitalizations and lower healthcare costs.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup><sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> For example, for Medicare beneficiaries between 2002 and 2010, obtaining prescription drug insurance through Medicare Part D was associated with an 8% decrease in the number of hospital admissions, a 7% decrease in Medicare expenditures, and a 12% decrease in total resource use.<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Reasons_for_high_prices\">Reasons for high prices</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=8\" title=\"Edit section: Reasons for high prices\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Variability_and_non-transparency\">Variability and non-transparency</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=9\" title=\"Edit section: Variability and non-transparency\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>As of 2015, the price of a pharmaceutical drug depends on who is paying and numerous other variabilities, per the acting administrator of the federal Medicare and Medicaid programmes: <a href=\"/wiki/List_price\" title=\"List price\">list price</a>, <a href=\"/wiki/Wholesale_price\" class=\"mw-redirect\" title=\"Wholesale price\">wholesale price</a>, <a href=\"/wiki/Average_wholesale_price_(pharmaceuticals)\" title=\"Average wholesale price (pharmaceuticals)\">average wholesale price (pharmaceuticals)</a>, rebates, supplemental rebates, <a href=\"/wiki/Markup_(business)\" title=\"Markup (business)\">markups</a> from hospitals, markups for physicians, drug price for inpatients versus outpatients, <a href=\"/wiki/Formulary_(pharmacy)\" title=\"Formulary (pharmacy)\">formulary (pharmacy)</a> tiers, mail order price, <a href=\"/wiki/Biosimilar\" title=\"Biosimilar\">biosimilar</a> prices, \"patent expirations, compounds, samples, and many other ways that end up obscuring the reality of the price paid, who pays it, and how all of it influences treatment decisions.\"<sup id=\"cite_ref-lancet15_30-0\" class=\"reference\"><a href=\"#cite_note-lancet15-30\">&#91;30&#93;</a></sup><sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Market_exclusivity\">Market exclusivity</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=10\" title=\"Edit section: Market exclusivity\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In a market without price controls, competition is key to driving the price of drug products down. However, legal protection in the form of patents result in a government-approved monopoly on the sale of certain drugs. Typically, patents allow for market exclusivity for a maximum period of 20 years after patent approval.<sup id=\"cite_ref-:4_32-0\" class=\"reference\"><a href=\"#cite_note-:4-32\">&#91;32&#93;</a></sup> However, given that FDA approval of a drug can take anywhere from 10\u201312 years, pharmaceutical companies can be granted a patent extension that is valid for a maximum of 14 years after FDA approval of the drug.<sup id=\"cite_ref-:4_32-1\" class=\"reference\"><a href=\"#cite_note-:4-32\">&#91;32&#93;</a></sup>\n</p><p>But even as the patent term nears expiration, pharmaceutical manufacturers employ several strategies to delay the entry of generic drugs to market. This could include by obtaining additional patents on other aspects of a drug, such as \"its coating, salt moiety, formulation, and method of administration\".<sup id=\"cite_ref-:5_5-1\" class=\"reference\"><a href=\"#cite_note-:5-5\">&#91;5&#93;</a></sup> An example of this strategy is the company AstraZeneca PLC (\u201cAstraZeneca\u201d) obtaining a patent on the <a href=\"/wiki/Enantiomer\" title=\"Enantiomer\">enantiomer</a> of omeprazole (Prilosec), a heartburn medication. The patent was obtained without significant evidence of the enantiomer\u2019s improved efficacy. As a result, AstraZeneca was able to sell its rebranded product esomeprazole (Nexium) at a 600% markup.<sup id=\"cite_ref-:5_5-2\" class=\"reference\"><a href=\"#cite_note-:5-5\">&#91;5&#93;</a></sup>\n</p><p>Pharmaceutical companies have also employed the \"pay-to-delay\" strategy in which they enter into reverse payment agreement with generic company to delay the generic drug's manufacture.<sup id=\"cite_ref-:6_33-0\" class=\"reference\"><a href=\"#cite_note-:6-33\">&#91;33&#93;</a></sup> This was the case in 2008, when an agreement between AstraZeneca and Ranbaxy Laboratories Ltd. (\u201cRanbaxy\u201d) was reached to delay Ranbaxy\u2019s launch of a generic version of AstraZeneca\u2019s patented heartburn drug Nexium until 2014.<sup id=\"cite_ref-:6_33-1\" class=\"reference\"><a href=\"#cite_note-:6-33\">&#91;33&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Drug_company_profits\">Drug company profits</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=11\" title=\"Edit section: Drug company profits\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>A Kaiser Family Foundation survey from June 2015 found the public citing \"drug company profits as the number one reason for the high cost of prescription drugs (picked by 77%), followed by the cost of medical research (64%), the cost of marketing and advertising (54%), and the cost of lawsuits against pharmaceutical companies (49%).\"<sup id=\"cite_ref-kaiser_34-0\" class=\"reference\"><a href=\"#cite_note-kaiser-34\">&#91;34&#93;</a></sup> CBS's MoneyWatch reports that in half of the 16 publicly held drugs companies in its study, profits exceeded R&amp;D cost while in all but one of the companies, \"corporate overhead\" (which includes sales, administrative, and marketing) exceeded profits.<sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup>\n</p><p>As of 2015, several pharmaceutical companies had developed a new <a href=\"/wiki/Business_strategy\" class=\"mw-redirect\" title=\"Business strategy\">business strategy</a> \"of dominating noncompetitive markets for older drugs and then increasing the price substantially\".<sup id=\"cite_ref-greene_36-0\" class=\"reference\"><a href=\"#cite_note-greene-36\">&#91;36&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmacy_benefit_managers\">Pharmacy benefit managers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=12\" title=\"Edit section: Pharmacy benefit managers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Pharmacy_benefit_manager\" class=\"mw-redirect\" title=\"Pharmacy benefit manager\">Pharmacy benefit managers</a> (PBMs) may increase drug prices they charge to their clients, in order to increase their profits. For example, they may classify generic drugs as brand name drugs, because their contract does not contain a definition, or only an ambiguous, or a variable definition. This allows PBM's to classify drugs \"for one purpose in one way, and for another purpose in another way\", and to change the classification at different points during the life of a contract. This, as of 2010 unlitigated freedom, affects \"drug coverage, making contract terms, and the reporting about the satisfaction of contract terms\".<sup id=\"cite_ref-Cahn_37-0\" class=\"reference\"><a href=\"#cite_note-Cahn-37\">&#91;37&#93;</a></sup>\n</p><p>PBM's can make confidential business agreements with pharmaceutical companies, which PBM's have called <a href=\"/wiki/Collective_buying_power\" title=\"Collective buying power\">collective buying power</a>, then set a (lower) reimbursement maximum amounts to drugstores for generic drugs and set (higher) charges to insurers. This practice is also known as \"spread pricing\".<sup id=\"cite_ref-usa14_38-0\" class=\"reference\"><a href=\"#cite_note-usa14-38\">&#91;38&#93;</a></sup>\nThere are examples where PBMs can double drug costs.<sup id=\"cite_ref-usa14_38-1\" class=\"reference\"><a href=\"#cite_note-usa14-38\">&#91;38&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Drug_rebates\">Drug rebates</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=13\" title=\"Edit section: Drug rebates\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Drug manufacturers may offer to pay an insurance company a <a href=\"/wiki/Rebate_(marketing)\" title=\"Rebate (marketing)\">rebate</a> after they have sold them a drug for full price. This is largely invisible to the consumer, because a drug company does not report how much money it returns to the payer. In 2012, the aggregate in the US has been estimated at $40 billion per year.<sup id=\"cite_ref-forbes_39-0\" class=\"reference\"><a href=\"#cite_note-forbes-39\">&#91;39&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Orphan_drugs\">Orphan drugs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=14\" title=\"Edit section: Orphan drugs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Drug companies can price new medicines, particularly <a href=\"/wiki/Orphan_drug\" title=\"Orphan drug\">orphan drugs</a>, i.e. drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients, at a cost that no individual person could pay, because an insurance company or the government are payors.<sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup>\nAn orphan drug may cost as much as $400,000 annually. The orphan drug business model could come under increased payer regulation.<sup id=\"cite_ref-41\" class=\"reference\"><a href=\"#cite_note-41\">&#91;41&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"FDA_backlog_in_generic_drug_application_review\">FDA backlog in generic drug application review</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=15\" title=\"Edit section: FDA backlog in generic drug application review\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<table class=\"plainlinks metadata ambox ambox-content ambox-POV\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"Unbalanced scales.svg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/45px-Unbalanced_scales.svg.png\" width=\"45\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/68px-Unbalanced_scales.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fe/Unbalanced_scales.svg/90px-Unbalanced_scales.svg.png 2x\" data-file-width=\"400\" data-file-height=\"354\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">The <b><a href=\"/wiki/Wikipedia:Neutral_point_of_view\" title=\"Wikipedia:Neutral point of view\">neutrality</a> of this section is <a href=\"/wiki/Wikipedia:NPOV_dispute\" title=\"Wikipedia:NPOV dispute\">disputed</a></b>.<span class=\"hide-when-compact\"> Relevant discussion may be found on the <a href=\"/wiki/Talk:Prescription_drug_prices_in_the_United_States##\" title=\"Talk:Prescription drug prices in the United States\">talk page</a>. Please do not remove this message until <a href=\"/wiki/Template:POV#When_to_remove\" title=\"Template:POV\">conditions to do so are met</a>.</span>  <small><i>(September 2016)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<p>The national debate over the rising cost of prescription medicines drew attention to the huge backlog of generic drug applications at the <a href=\"/wiki/US_Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"US Food and Drug Administration\">US Food and Drug Administration</a> (FDA).<sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup>\n</p><p>Usually, when enough generic drug products are introduced to the market, the cost to buy prescription medications decreases for both the insurer and the patient.<sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup><sup id=\"cite_ref-44\" class=\"reference\"><a href=\"#cite_note-44\">&#91;44&#93;</a></sup> Generic drugs have been shown to reduce healthcare costs in multiple ways, among them increasing competition which, in most cases, helps drive prices down.<sup id=\"cite_ref-45\" class=\"reference\"><a href=\"#cite_note-45\">&#91;45&#93;</a></sup> <a rel=\"nofollow\" class=\"external free\" href=\"https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm129445.gif\">https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm129445.gif</a>\n</p><p>Companies that want to manufacture generic drugs must show in their applications to the FDA that they guarantee quality and <a href=\"/wiki/Bioequivalence\" title=\"Bioequivalence\">bioequivalence</a>. In July 2016, the FDA generic drug application backlog comprised 4,036 generics. On the other hand, the European Medicine Agency (EMA), Europe's equivalent to the FDA, had only 24 generics drug applications awaiting approval. This count includes biologically based biosimilars awaiting approval. The FDA's generic count doesn't include biosimilars, which are more complicated medicines to review. According to Generic Pharmaceutical Association, the median time it takes for the FDA to approve a generic is 47 months.<sup id=\"cite_ref-46\" class=\"reference\"><a href=\"#cite_note-46\">&#91;46&#93;</a></sup>\n</p><p>On July 9, 2012, Generic Drug User Fee Amendments of 2012 (GDUFA) was signed into law.<sup id=\"cite_ref-:8_47-0\" class=\"reference\"><a href=\"#cite_note-:8-47\">&#91;47&#93;</a></sup> The GDUFA was designed to build upon the  20-year-old Prescription Drug Fee Act and improve the generic drug review and <sup id=\"cite_ref-:8_47-1\" class=\"reference\"><a href=\"#cite_note-:8-47\">&#91;47&#93;</a></sup> approval process.<sup id=\"cite_ref-:7_48-0\" class=\"reference\"><a href=\"#cite_note-:7-48\">&#91;48&#93;</a></sup>  According to the FDA website, the GDUFA enables the FDA to levy user fees \"to fund critical and measurable enhancements to the performance of FDA\u2019s generic drugs program, bringing greater predictability and timeliness to the review of generic drug applications\".<sup id=\"cite_ref-:8_47-2\" class=\"reference\"><a href=\"#cite_note-:8-47\">&#91;47&#93;</a></sup> The hiring of over 1,000 employees and the upgrade of the office's information technology were among the improvements generated by these funds.<sup id=\"cite_ref-:7_48-1\" class=\"reference\"><a href=\"#cite_note-:7-48\">&#91;48&#93;</a></sup>\n</p><p>The EMA along with the European Commission, which handles approval of marketing materials, are approving generics and brand-name drugs in about a year on average, according to the EMA. In fiscal year 2014, the FDA had not approved any of about 1500 such applications by the end of 2014.<sup id=\"cite_ref-49\" class=\"reference\"><a href=\"#cite_note-49\">&#91;49&#93;</a></sup> The slow pace of the FDA review (6\u201312 months even for a priority review) has not allowed the market to correct itself in a timely manner, i.e. not allowed manufacturers to begin to produce and offer a product, when a price is too high. The following suggestions have been made: prioritize review of applications for essential drugs, i.e. move them up in the queue. If the FDA felt unable to make this largely economic evaluation about priority, the Department of Health and Human Services (DHHS) Office of the Assistant Secretary for Planning and Evaluation could do this. Second, the FDA could temporarily permit compounding. And third, the FDA could \"temporarily permit the importation of drug products reviewed/approved by competent regulatory authorities outside the United States\".<sup id=\"cite_ref-greene_36-1\" class=\"reference\"><a href=\"#cite_note-greene-36\">&#91;36&#93;</a></sup>\n</p><p>In a January 2016 senate hearing, the director of the FDA\u2019s <a href=\"/wiki/Center_for_Drug_Evaluation_and_Research\" title=\"Center for Drug Evaluation and Research\">Center for Drug Evaluation and Research</a> said, that increasing numbers of generic drug applications had \"overwhelmed the FDA staff and created unpredictability and delay for industry\",<sup id=\"cite_ref-wood_50-0\" class=\"reference\"><a href=\"#cite_note-wood-50\">&#91;50&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>2</span></sup> but that the FDA is ahead of schedule in reducing the backlog since then.<sup id=\"cite_ref-wood_50-1\" class=\"reference\"><a href=\"#cite_note-wood-50\">&#91;50&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>11</span></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Research_and_development\">Research and development</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=16\" title=\"Edit section: Research and development\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Pharmaceutical companies argue that the prices they set for a drug are necessary to fund research. 11% of drug candidates that enter clinical trials are successful and receive approval for sale.<sup id=\"cite_ref-51\" class=\"reference\"><a href=\"#cite_note-51\">&#91;51&#93;</a></sup> Although the cost of manufacturing is relatively low, the cost of <a href=\"/wiki/Drug_development\" title=\"Drug development\">developing a new drug</a> is relatively high.<sup id=\"cite_ref-SmithandODonnell_52-0\" class=\"reference\"><a href=\"#cite_note-SmithandODonnell-52\">&#91;52&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>422</span></sup> In 2011, \"a single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion.\"<sup id=\"cite_ref-53\" class=\"reference\"><a href=\"#cite_note-53\">&#91;53&#93;</a></sup> It has been stated that the U.S. pharmaceutical industry is able to invent drugs that would not be profitable in countries with lower prices, because of the high drug prices in the United States.<sup id=\"cite_ref-SmithandODonnell_52-1\" class=\"reference\"><a href=\"#cite_note-SmithandODonnell-52\">&#91;52&#93;</a></sup>\n</p><p>Critics of pharmaceutical companies point out that only a small portion of the drug companies' expenditures are used for research and development, with the majority of their money being spent in the areas of marketing and administration.<sup id=\"cite_ref-54\" class=\"reference\"><a href=\"#cite_note-54\">&#91;54&#93;</a></sup>\n</p><p>European pharmaceutical companies are as innovative, or perhaps even more so, than their U.S. counterparts, despite price controls. In addition, some countries, such as the United Kingdom and Germany, encourage <a href=\"/wiki/Comparative_effectiveness_research\" title=\"Comparative effectiveness research\">comparative effectiveness reviews</a>, whereby <a href=\"/wiki/Cost-benefit_analyses\" class=\"mw-redirect\" title=\"Cost-benefit analyses\">cost-benefit analyses</a> of rival drugs determine which perform best.<sup id=\"cite_ref-:0_55-0\" class=\"reference\"><a href=\"#cite_note-:0-55\">&#91;55&#93;</a></sup><sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citing_sources\" title=\"Wikipedia:Citing sources\"><span title=\"This citation requires a reference to the specific page or range of pages in which the material appears. (February 2016)\">page&#160;needed</span></a></i>&#93;</sup>\n</p><p>Charles L. Hooper and <a href=\"/wiki/David_R._Henderson\" title=\"David R. Henderson\">David R. Henderson</a> wrote in a 2016 publication of the <a href=\"/wiki/Cato_Institute\" title=\"Cato Institute\">Cato Institute</a> that drug company's pricing correlates with the per capita income of foreign countries and they opined, that in some cases foreign governments drive such hard bargains to the point that they do not contribute to the cost of R&amp;D, leaving \"Americans to subsidize the R&amp;D costs\" .<sup id=\"cite_ref-56\" class=\"reference\"><a href=\"#cite_note-56\">&#91;56&#93;</a></sup> Jeanne Whalen wrote in the Wall Street Journal in 2015, \"The upshot is Americans fund much of the global drug industry\u2019s earnings, and its efforts to find new medicines.\" and that the U.S. market was \"responsible for the majority of profits for most large pharmaceutical companies.\"<sup id=\"cite_ref-57\" class=\"reference\"><a href=\"#cite_note-57\">&#91;57&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Solutions\">Solutions</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=17\" title=\"Edit section: Solutions\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Discounts\">Discounts</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=18\" title=\"Edit section: Discounts\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Programs and strategies are available to cut prescription drug costs. When it comes to US drug prices, many factors are at hand to result in unaffordable drug prices for patients. There are programs in place to help the consumer navigate to obtain affordable drugs. One of the following programs is the 340B pricing program that allows hospitals and pharmacists to buy drugs at 30-50% off the retail prices.<sup id=\"cite_ref-:9_58-0\" class=\"reference\"><a href=\"#cite_note-:9-58\">&#91;58&#93;</a></sup> Per HRSA's <a href=\"/wiki/340B_Drug_Pricing_Program\" title=\"340B Drug Pricing Program\">340B Drug Pricing Program</a>, drug manufacturers are required to give certain organizations discounted drugs given these organizations fit the eligibility criteria for discounts.<sup id=\"cite_ref-59\" class=\"reference\"><a href=\"#cite_note-59\">&#91;59&#93;</a></sup> A big problem with 340B or similar programs is that pharmacies and hospitals can choose to bill for the discounted drugs at full price, defeating the purpose of the program to control drug prices and maintain affordability for low-income patients.<sup id=\"cite_ref-:9_58-1\" class=\"reference\"><a href=\"#cite_note-:9-58\">&#91;58&#93;</a></sup>\n</p><p>Prices vary from one pharmacy to another as listed prices determine what the insurance companies will have to pay for the drug. Therefore, patients are rarely expected to pay the high prices listed for each prescription. According to the 2017 consumer reports, it is important to compare prices of various retail pharmacies to get the best deal.<sup id=\"cite_ref-:10_60-0\" class=\"reference\"><a href=\"#cite_note-:10-60\">&#91;60&#93;</a></sup> Other tips include seeking 90-day prescription when possible, asking for the lowest price when deciding to pay for a medication, asking for generics (refer to \"Generics versus Brand-name Products\" for more details regarding generic drugs vs. brand-name drugs), comparing insurance plans and talking to your doctor about costs in order to find cheaper alternative(s).<sup id=\"cite_ref-61\" class=\"reference\"><a href=\"#cite_note-61\">&#91;61&#93;</a></sup><sup id=\"cite_ref-:10_60-1\" class=\"reference\"><a href=\"#cite_note-:10-60\">&#91;60&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Drug_Coupons\">Drug Coupons</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=19\" title=\"Edit section: Drug Coupons\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Offering drug coupons is a strategy employed by pharmaceutical companies to lower consumer out-of-pocket costs. Patients can obtain these coupons online or at their doctor\u2019s office and use them to reduce their co-pays for a given prescription medication. For certain specialty drugs, drug coupons have been found to save patients as much as $6 of every $10 they are asked to pay out-of-pocket.<sup id=\"cite_ref-62\" class=\"reference\"><a href=\"#cite_note-62\">&#91;62&#93;</a></sup> For a certain type of drug, drug coupon users had higher drug utilization rates and lower rates of discontinuation than for non coupon users.<sup id=\"cite_ref-63\" class=\"reference\"><a href=\"#cite_note-63\">&#91;63&#93;</a></sup>\n</p><p>While this approach has been praised for lowering out-of-pocket costs and consequently reducing cost-related nonadherence,<sup id=\"cite_ref-64\" class=\"reference\"><a href=\"#cite_note-64\">&#91;64&#93;</a></sup> some argue that coupons simply incentivize patients to initiate expensive brand-name drugs, ultimately leading to more expensive premiums that cancel out any previous cost-saving effects of the coupons.<sup id=\"cite_ref-65\" class=\"reference\"><a href=\"#cite_note-65\">&#91;65&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Generics_versus_brand-name_products\">Generics versus brand-name products</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=20\" title=\"Edit section: Generics versus brand-name products\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>A generic drug is a chemically equivalent, cheaper version of a brand-name drug. A generic drug form is required to have the same dose, strength and active ingredient(s) as the brand name drug; thus, they carry the same risks and benefits. To ensure compliance, the FDA Generic Drugs Program conducts stringent reviews (3,500 inspections of manufacturing plants per year).<sup id=\"cite_ref-:11_66-0\" class=\"reference\"><a href=\"#cite_note-:11-66\">&#91;66&#93;</a></sup> Although generic drugs sound like a great money-saver, generic medicines can only be sold after the patents of the brand name versions end.<sup id=\"cite_ref-:11_66-1\" class=\"reference\"><a href=\"#cite_note-:11-66\">&#91;66&#93;</a></sup> Because of this mandatory period of exclusivity for many brand-name drugs (a period in which generic medicines cannot be sold), delay of generic drugs reaching the market is expected. The high cost of upfront research that the brand-name products have to go through to ensure safety and efficacy largely account for the high discrepancy in pricing between the two groups.\n</p>\n<h3><span class=\"mw-headline\" id=\"Value-based_prices\">Value-based prices</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=21\" title=\"Edit section: Value-based prices\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>An effort is being made to determine if the value of a drug justifies its price. Such measures include cost-minimization, cost-benefit, cost-effectiveness, and cost-utility analysis.<sup id=\"cite_ref-:02_67-0\" class=\"reference\"><a href=\"#cite_note-:02-67\">&#91;67&#93;</a></sup> They take into account the total costs, including hospital stays, repeated dosages, etc. and, comparing it to a similar treatment, determines whether a drug will actually minimize costs and whether it is more effective in curing the patient. These cost analyses can all be calculated from the point of view of the hospital, the healthcare system, the government, and the patient, so what is best for one party may not be best for another in terms of cost, making the value of a drug in terms of its price, sometimes a difficult thing to measure.\n</p><p><a href=\"/wiki/Quality-adjusted_life_year\" title=\"Quality-adjusted life year\">Quality-Adjusted Life Years</a> (QALY) is a cost-effective measure that determines the value of a drug in terms of the quality of life achieved after taking a prescription drug, rather than the number of years the medication extends a patient's life.<sup id=\"cite_ref-:02_67-1\" class=\"reference\"><a href=\"#cite_note-:02-67\">&#91;67&#93;</a></sup> However, QALY is subjective to each patient and brings up moral dilemmas such as whether or not it is cost-effective to do a life-saving operation for someone who is elderly or has other complications. The subjectiveness of QALY is apparent on a case by case basis as it takes into account both the quality and quantity of life lived by an individual, with quality of life being the primary subjective factor. QALY does not completely reflect an individual's personal preferences in a particular clinical situation as their value based perspective of life is completely subjective.<sup id=\"cite_ref-68\" class=\"reference\"><a href=\"#cite_note-68\">&#91;68&#93;</a></sup>\n</p><p>In <a href=\"/wiki/Oncology\" title=\"Oncology\">oncology</a>, the <a href=\"/wiki/American_Society_of_Clinical_Oncology\" title=\"American Society of Clinical Oncology\">American Society of Clinical Oncology</a> and the <a href=\"/wiki/European_Society_for_Medical_Oncology\" title=\"European Society for Medical Oncology\">European Society for Medical Oncology</a>  both developed specific tools in 2015 to grade the value of new drugs.<sup id=\"cite_ref-69\" class=\"reference\"><a href=\"#cite_note-69\">&#91;69&#93;</a></sup><sup id=\"cite_ref-:12_70-0\" class=\"reference\"><a href=\"#cite_note-:12-70\">&#91;70&#93;</a></sup><sup id=\"cite_ref-71\" class=\"reference\"><a href=\"#cite_note-71\">&#91;71&#93;</a></sup> to discuss the price/value ratio of anti-cancer drugs between physicians and patients and on a societal level.<sup id=\"cite_ref-:12_70-1\" class=\"reference\"><a href=\"#cite_note-:12-70\">&#91;70&#93;</a></sup><sup id=\"cite_ref-:13_72-0\" class=\"reference\"><a href=\"#cite_note-:13-72\">&#91;72&#93;</a></sup> A 2017 review of anti-cancer drugs approved by the FDA between 2000 and 2015 found no relationship between their price and their value as measured by the scales of the ASCO and the ESMO.<sup id=\"cite_ref-73\" class=\"reference\"><a href=\"#cite_note-73\">&#91;73&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Policy_makers\">Policy makers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=22\" title=\"Edit section: Policy makers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The FDA has a \"priority review process\" for drugs which compete with another drug whose price exceeds its value-based price. Congress could also grant the FDA the ability to change the exclusivity period for new drugs.<sup id=\"cite_ref-JAMA2_2-1\" class=\"reference\"><a href=\"#cite_note-JAMA2-2\">&#91;2&#93;</a></sup>  The FDA could also temporarily allow the import of drugs approved for sale outside the United States.<sup id=\"cite_ref-greene_36-2\" class=\"reference\"><a href=\"#cite_note-greene-36\">&#91;36&#93;</a></sup>\n</p><p>In December 2015, the DHHS held a public meeting and both houses of Congress had hearings on off-patent drugs with limited or no competition.<sup id=\"cite_ref-74\" class=\"reference\"><a href=\"#cite_note-74\">&#91;74&#93;</a></sup>\n</p><p>In 2017, Democratic party leaders announced a plan to enforce limits on how much pharmaceutical companies could raise drug prices. Under the plan, drugs with a \u201csignificant price increase\u201d would have to explain the price rise to the HHS a minimum of 30 days before implementing the price hike. Although Turing Pharmaceuticals\u2019 Daraprim price rise of 5000% overnight would meet the proposal\u2019s definition of a \u201csignificant price increase,\u201d under the proposed plan, Mylan's well-publicized price increase for EpiPen would fall below the thresholds in the plan\u2019s criteria for enforcement.<sup id=\"cite_ref-75\" class=\"reference\"><a href=\"#cite_note-75\">&#91;75&#93;</a></sup><sup id=\"cite_ref-Senate_Bill_17_76-0\" class=\"reference\"><a href=\"#cite_note-Senate_Bill_17-76\">&#91;76&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"New_legislation\">New legislation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=23\" title=\"Edit section: New legislation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>On October 9, 2017 Governor <a href=\"/wiki/Jerry_Brown\" title=\"Jerry Brown\">Jerry Brown</a> of <a href=\"/wiki/California\" title=\"California\">California</a> passed Senate Bill 17 (SB-17) Health care: prescription drug costs. \nThis bill focuses on transparency regarding pharmaceutical companies. This bill mainly focuses on two aspects. The first being that drug companies\nmust give prior notice of price increases for prescription drugs. Drug Manufacturers must \nnotify state purchasers such as <a href=\"/wiki/CalPERS\" title=\"CalPERS\">CalPERS</a>, Medi-Cal etc. 90 days prior to the planned effective date. The second focus is on \nthe transparency of spending trends. This means that health plans and insurers have to annually report all covered drugs (categorized by generic drugs, brand names, and specialty drugs).<sup id=\"cite_ref-Senate_Bill_17_76-1\" class=\"reference\"><a href=\"#cite_note-Senate_Bill_17-76\">&#91;76&#93;</a></sup><sup id=\"cite_ref-77\" class=\"reference\"><a href=\"#cite_note-77\">&#91;77&#93;</a></sup>\n</p>\n<ul><li>the 25 most prescribed drugs</li>\n<li>the 25 most costly drugs</li>\n<li>the 25 drugs with the highest year-over-year increase in total annual spending.<sup id=\"cite_ref-Senate_Bill_17_76-2\" class=\"reference\"><a href=\"#cite_note-Senate_Bill_17-76\">&#91;76&#93;</a></sup></li></ul>\n<p>This information will help the public and policy makers see spending trends on medications and be able to shift focus on how best to utilize the healthcare dollar.\n</p>\n<h3><span id=\"Canada.27s_model\"></span><span class=\"mw-headline\" id=\"Canada's_model\">Canada's model</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=24\" title=\"Edit section: Canada&#039;s model\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In Canada, the <a href=\"/wiki/Patented_Medicine_Prices_Review_Board\" title=\"Patented Medicine Prices Review Board\">Patented Medicine Prices Review Board</a> determines a maximum price for all drugs. In 1987, Bill C-22 established an extended period of protection for patents prior to licensing, which would allow for generics to enter the market. It also created the <a href=\"/wiki/Patented_Medicine_Prices_Review_Board\" title=\"Patented Medicine Prices Review Board\">Patented Medicine Prices Review Board</a> (PMPRB), an independent semi-judicial body, which had the purpose of establishing review guidelines of individual drug prices, conduct investigations for allegations of excessive pricing, and negotiations to a voluntary compliance agreement. These efforts are to ensure that manufacturer prices are within justification, and not excessive. Excessive is interpreted based on the following criteria:<sup id=\"cite_ref-78\" class=\"reference\"><a href=\"#cite_note-78\">&#91;78&#93;</a></sup>\n</p><p><i>\u201c1. The price of an existing patented drug cannot increase by more than the Consumer Price Index (CPI)</i>\n</p><p><i>2. The price of a new drug (in most cases) is limited so that the cost of therapy with the new drug is in the range of the costs of therapy with existing drugs in the same therapeutic class.</i>\n</p><p><i>3. The price of a breakthrough drug is limited to the median of its prices in France, Germany, Italy, Sweden, Switzerland, Britain, and the United States. In addition, no patented drug can be priced above the highest price in this group of countries</i>.\u201d<i></i>\n</p><p>Low levels of drug spending in Canada are not solely attributable to the regulatory activities of the government, but also the actions of provincial and private insurance plans. These plans prevents price inflation through formulary management, independent clinical review of new products, reference-based pricing, the LCA, and limited use program.<sup id=\"cite_ref-79\" class=\"reference\"><a href=\"#cite_note-79\">&#91;79&#93;</a></sup>\nIn reviewing formularies, the drug program reviews the therapeutic advantage of one product over the existing formulary, and only adds new drugs if program costs are unchanged. The reference-based pricing entails having a \u201creference product\u201d for each category that is the baseline price, and utilizes an independent panel of pharmacists and doctors the University of British Columbia to evaluate the therapeutic discrepancies between drugs.The LCA, or low-cost alternative program establishes the price of generics for payment regardless if brand or genetics are used. The limited use program requires prior authorization for specific drugs, and restricts reimbursements to the approved rationale of prior authorizations (i.e. patients who have failed previous agents for the same indication).\n</p><p>The government is purchasing drugs similar to how the United States purchases medications for military personnel, but on a much wider scale.<sup id=\"cite_ref-:0_55-1\" class=\"reference\"><a href=\"#cite_note-:0-55\">&#91;55&#93;</a></sup><sup class=\"reference\" style=\"white-space:nowrap;\">:<span>280</span></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Healthcare_providers\">Healthcare providers</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=25\" title=\"Edit section: Healthcare providers\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Healthcare providers can help lower drug prices by helping patients navigate the medication formulary, prescribing drugs covered by formularies, and participating in formulary development through <a href=\"/wiki/Pharmacy_and_Therapeutics\" title=\"Pharmacy and Therapeutics\">Pharmacy and Therapeutics</a> committees. The formulary system\u2019s effectiveness is directly correlated to the education of physicians, pharmacists and patients in understanding the justification of formulary compositions. This education includes drug information monographs to provide adequate resources to physicians in making clinical prescribing decisions, pharmacy education regarding any changes in the formulary, and patient education within the managed care system.<sup id=\"cite_ref-80\" class=\"reference\"><a href=\"#cite_note-80\">&#91;80&#93;</a></sup>\n</p><p>Formularies should be easily accessible for patient access as well, such as the online <a rel=\"nofollow\" class=\"external text\" href=\"https://www.medicare.gov/find-a-plan/questions/home.aspx/\">Medicare Planfinder</a>, which is part of the Medicare Part D Plan.\n</p><p>Healthcare providers can substitute three-month for one-month supplies of medicines. A three-month supply represented a 29% decrease in out-of-pocket costs and an 18% decrease in total prescription costs in one study.<sup id=\"cite_ref-81\" class=\"reference\"><a href=\"#cite_note-81\">&#91;81&#93;</a></sup>\n</p><p>Prescribing combination drugs instead of two separate medications can also potentially reduce monthly copays.<sup id=\"cite_ref-82\" class=\"reference\"><a href=\"#cite_note-82\">&#91;82&#93;</a></sup>\n</p><p>Because the FDA has no regulations on drug companies in providing evidence that a new drug has a therapeutic advantage over an older drug, many physicians have a tendency to write prescriptions for drugs they are most familiar with. Oftentimes, these prescribing practices are influenced by manufacturer marketing to private practices or hospitals.<sup id=\"cite_ref-83\" class=\"reference\"><a href=\"#cite_note-83\">&#91;83&#93;</a></sup> Prescriber monitoring programs should be implemented to help physicians make cost-effective, evidence-based prescribing decisions, and foundation protocols should be established. This is important to ensure that the most clinically-effective drugs are selected, and if a more expensive drug is selected, that appropriate therapeutic equivalence is evaluated with research supporting this decision. However, some organizations believe that if the federal government modified reimportation laws, the FDA could conduct a comprehensive assessment on manufacturing standards in other countries, and allow importation of drugs that meet or exceed U.S. safety standards for drug manufacturing.<sup id=\"cite_ref-American_Hospital_Association:_Drug_Policy_Recommendations_84-0\" class=\"reference\"><a href=\"#cite_note-American_Hospital_Association:_Drug_Policy_Recommendations-84\">&#91;84&#93;</a></sup>\n</p><p>Individual importation of lower cost prescription drugs from foreign countries \u2013 as done by 2% of U.S. consumers in 2011 and 2012 \u2013 is likely not an effective public health solution.<sup id=\"cite_ref-85\" class=\"reference\"><a href=\"#cite_note-85\">&#91;85&#93;</a></sup> However, if the federal government modified reimportation laws, the FDA could conduct a comprehensive assessment on manufacturing standards in other countries, and allow importation of drugs that meet or exceed U.S. safety standards for drug manufacturing.\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=26\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Medicare_Prescription_Drug,_Improvement,_and_Modernization_Act\" title=\"Medicare Prescription Drug, Improvement, and Modernization Act\">Medicare Prescription Drug, Improvement, and Modernization Act</a></li>\n<li><a href=\"/wiki/Essential_medicines_policies\" title=\"Essential medicines policies\">Essential medicines policies</a></li>\n<li><a href=\"/wiki/Prescription_costs\" title=\"Prescription costs\">Prescription costs</a></li>\n<li><a href=\"/wiki/Prescription_charges\" title=\"Prescription charges\">Prescription charges</a></li>\n<li><a href=\"/wiki/Sri_Lanka_National_Pharmaceuticals_Policy\" title=\"Sri Lanka National Pharmaceuticals Policy\">Sri Lanka National Pharmaceuticals Policy</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=27\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet (23 August 2016). \"The High Cost of Prescription Drugs in the United States\". <i>JAMA</i>. <b>316</b> (8): 858. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2016.11237\">10.1001/jama.2016.11237</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+High+Cost+of+Prescription+Drugs+in+the+United+States&amp;rft.volume=316&amp;rft.issue=8&amp;rft.pages=858&amp;rft.date=2016-08-23&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2016.11237&amp;rft.aulast=Kesselheim&amp;rft.aufirst=Aaron+S.&amp;rft.au=Avorn%2C+Jerry&amp;rft.au=Sarpatwari%2C+Ameet&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-JAMA2-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-JAMA2_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-JAMA2_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Bach, Peter B.; Pearson, Steven D. (2015-12-15). \"Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs\". <i>JAMA</i>. <b>314</b> (23): 2503\u20132504. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2015.16843\">10.1001/jama.2015.16843</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1538-3598\">1538-3598</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26619354\">26619354</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=Payer+and+Policy+Maker+Steps+to+Support+Value-Based+Pricing+for+Drugs&amp;rft.volume=314&amp;rft.issue=23&amp;rft.pages=2503-2504&amp;rft.date=2015-12-15&amp;rft.issn=1538-3598&amp;rft_id=info%3Apmid%2F26619354&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2015.16843&amp;rft.aulast=Bach&amp;rft.aufirst=Peter+B.&amp;rft.au=Pearson%2C+Steven+D.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-morgan-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-morgan_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Morgan, Steven &amp; Hurley, Jeremiah (2004-03-16). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cmaj.ca/cgi/content/full/170/6/945?etoc\">\"Internet pharmacy: prices on the up-and-up\"</a>. <i>CMAJ</i>. <b>170</b> (6): 945\u2013946. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1503/cmaj.104001\">10.1503/cmaj.104001</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC359422\">359422</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15023915\">15023915</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">11 July</span> 2007</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CMAJ&amp;rft.atitle=Internet+pharmacy%3A+prices+on+the+up-and-up&amp;rft.volume=170&amp;rft.issue=6&amp;rft.pages=945-946&amp;rft.date=2004-03-16&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422&amp;rft_id=info%3Apmid%2F15023915&amp;rft_id=info%3Adoi%2F10.1503%2Fcmaj.104001&amp;rft.au=Morgan%2C+Steven&amp;rft.au=Hurley%2C+Jeremiah&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcgi%2Fcontent%2Ffull%2F170%2F6%2F945%3Fetoc&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Donohue, Julie M. (2014). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nejm.org/doi/pdf/10.1056/NEJMp1402471\">\"The Impact and Evolution of Medicare Part D\"</a>. <i>New England Journal of Medicine</i>. <b>371</b> (8): 693\u2013695. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/nejmp1402471\">10.1056/nejmp1402471</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=The+Impact+and+Evolution+of+Medicare+Part+D&amp;rft.volume=371&amp;rft.issue=8&amp;rft.pages=693-695&amp;rft.date=2014&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmp1402471&amp;rft.aulast=Donohue&amp;rft.aufirst=Julie+M.&amp;rft_id=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Fpdf%2F10.1056%2FNEJMp1402471&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:5-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:5_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:5_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:5_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet (2016-08-23). <a rel=\"nofollow\" class=\"external text\" href=\"http://jamanetwork.com/journals/jama/fullarticle/2545691\">\"The High Cost of Prescription Drugs in the United States\"</a>. <i>JAMA</i>. <b>316</b> (8): 858. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2016.11237\">10.1001/jama.2016.11237</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0098-7484\">0098-7484</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+High+Cost+of+Prescription+Drugs+in+the+United+States&amp;rft.volume=316&amp;rft.issue=8&amp;rft.pages=858&amp;rft.date=2016-08-23&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2016.11237&amp;rft.issn=0098-7484&amp;rft.aulast=Kesselheim&amp;rft.aufirst=Aaron+S.&amp;rft.au=Avorn%2C+Jerry&amp;rft.au=Sarpatwari%2C+Ameet&amp;rft_id=http%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F2545691&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.commonwealthfund.org/publications/blog/2016/may/drug-price-control-how-some-government-programs-do-it\">\"Drug Price Control: How Some Government Programs Do It\"</a>. <i>www.commonwealthfund.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.commonwealthfund.org&amp;rft.atitle=Drug+Price+Control%3A+How+Some+Government+Programs+Do+It&amp;rft_id=http%3A%2F%2Fwww.commonwealthfund.org%2Fpublications%2Fblog%2F2016%2Fmay%2Fdrug-price-control-how-some-government-programs-do-it&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\">US Government Accountability Office (GAO) <a rel=\"nofollow\" class=\"external text\" href=\"http://www.gao.gov/products/GAO-05-779\">Prescription Drugs: Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004.</a> Report to Congressional Requesters. GAO-05-779. 15 August 2005.</span>\n</li>\n<li id=\"cite_note-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-8\">^</a></b></span> <span class=\"reference-text\">David Gross, Leigh Gross Purvis and Stephen W. Schondelmeyer,<a rel=\"nofollow\" class=\"external text\" href=\"http://www.aarp.org/research/health/drugs/aresearch-import-869-2004-06--IB69.html\">\"Trends in Manufacturer Prices of Prescription Drugs Used by Older Americans\"</a>, AARP, March 2007</span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\">Joseph Antos and Thomas F. Wildsmith, <a rel=\"nofollow\" class=\"external text\" href=\"http://www.aei.org/outlook/22818\">\"Inflated Claims about Drug Prices\"</a> <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20090714051407/http://www.aei.org/outlook/22818\">Archived</a> 2009-07-14 at the <a href=\"/wiki/Wayback_Machine\" title=\"Wayback Machine\">Wayback Machine</a>., <a href=\"/wiki/American_Enterprise_Institute\" title=\"American Enterprise Institute\">American Enterprise Institute</a>, 8 July 2005</span>\n</li>\n<li id=\"cite_note-NYT-20151219-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NYT-20151219_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">The Editorial Board (19 December 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-high-drug-prices.html\">\"No Justification for High Drug Prices\"</a>. <i>New York Times</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">20 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=No+Justification+for+High+Drug+Prices&amp;rft.date=2015-12-19&amp;rft.au=The+Editorial+Board&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F12%2F20%2Fopinion%2Fsunday%2Fno-justification-for-high-drug-prices.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\">US Senate Special Committee on Aging. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.aging.senate.gov/press-releases/collins-mccaskill-open-senate-investigation-into-rx-drug-pricing-announce-intention-to-hold-hearings\">Collins, McCaskill open Senate investigation into Rx drug pricing, announce intention to hold hearings. November 4, 2015. Accessed 4 January 2016.</a></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Duncan, Ian. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.baltimoresun.com/news/maryland/politics/bs-md-drug-price-gouging-20170410-story.html\">\"Maryland General Assembly passes bill aimed at drug 'price gouging<span style=\"padding-right:0.2em;\">'</span>\"</a>. <i>baltimoresun.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=baltimoresun.com&amp;rft.atitle=Maryland+General+Assembly+passes+bill+aimed+at+drug+%27price+gouging%27&amp;rft.aulast=Duncan&amp;rft.aufirst=Ian&amp;rft_id=http%3A%2F%2Fwww.baltimoresun.com%2Fnews%2Fmaryland%2Fpolitics%2Fbs-md-drug-price-gouging-20170410-story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-oecd-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-oecd_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-oecd_13-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://data.oecd.org/healthres/pharmaceutical-spending.htm\">Pharmaceutical spending (indicator)</a>. OECD Data, Health resources. 2013 doi: 10.1787/998febf6-en, accessed 27 November 2015</span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/nchs/data/hus/2014/103.pdf\">\"National health expenditures, average annual percent change, and percent distribution, by type of expenditure: United States, selected years 1960\u20132013\"</a> <span style=\"font-size:85%;\">(Table)</span>. <i>CDC</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=CDC&amp;rft.atitle=National+health+expenditures%2C+average+annual+percent+change%2C+and+percent+distribution%2C+by+type+of+expenditure%3A+United+States%2C+selected+years+1960%E2%80%932013&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Fhus%2F2014%2F103.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Martin, Anne B.; Lassman, David; Washington, Benjamin;  et al. (2012-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://content.healthaffairs.org/content/31/1/208\">\"Growth In US Health Spending Remained Slow In 2010; Health Share Of Gross Domestic Product Was Unchanged From 2009\"</a>. <i>Health Affairs</i>. <b>31</b> (1): 208\u2013219. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1377/hlthaff.2011.1135\">10.1377/hlthaff.2011.1135</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0278-2715\">0278-2715</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22232112\">22232112</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Growth+In+US+Health+Spending+Remained+Slow+In+2010%3B+Health+Share+Of+Gross+Domestic+Product+Was+Unchanged+From+2009&amp;rft.volume=31&amp;rft.issue=1&amp;rft.pages=208-219&amp;rft.date=2012-01-01&amp;rft.issn=0278-2715&amp;rft_id=info%3Apmid%2F22232112&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2011.1135&amp;rft.aulast=Martin&amp;rft.aufirst=Anne+B.&amp;rft.au=Lassman%2C+David&amp;rft.au=Washington%2C+Benjamin&amp;rft_id=http%3A%2F%2Fcontent.healthaffairs.org%2Fcontent%2F31%2F1%2F208&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"font-size:100%\" class=\"error citation-comment\"><code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;first5=</code> missing <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;last5=</code> in Authors list (<a href=\"/wiki/Help:CS1_errors#first_missing_last\" title=\"Help:CS1 errors\">help</a>)</span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Explicit use of et al. (<a href=\"/wiki/Category:CS1_maint:_Explicit_use_of_et_al.\" title=\"Category:CS1 maint: Explicit use of et al.\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cunningham, Peter J. (2010-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://content.healthaffairs.org/content/29/5/1037\">\"The Growing Financial Burden Of Health Care: National And State Trends, 2001\u20132006\"</a>. <i>Health Affairs</i>. <b>29</b> (5): 1037\u20131044. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1377/hlthaff.2009.0493\">10.1377/hlthaff.2009.0493</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0278-2715\">0278-2715</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20338908\">20338908</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=The+Growing+Financial+Burden+Of+Health+Care%3A+National+And+State+Trends%2C+2001%E2%80%932006&amp;rft.volume=29&amp;rft.issue=5&amp;rft.pages=1037-1044&amp;rft.date=2010-05-01&amp;rft.issn=0278-2715&amp;rft_id=info%3Apmid%2F20338908&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2009.0493&amp;rft.aulast=Cunningham&amp;rft.aufirst=Peter+J.&amp;rft_id=http%3A%2F%2Fcontent.healthaffairs.org%2Fcontent%2F29%2F5%2F1037&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:1-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:1_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:1_17-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Stagnitti, Marie N. Population Characteristics of Medicare Beneficiaries in the U.S. Civilian Noninstitutionalized Population, by Level of Annual Prescribed Medicines Expenses, 2003. Statistical Brief #138. September 2006. Agency for Healthcare Research and Quality, Rockville, MD. Web. 17 Sept. 2016.</span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cunningham, Peter J. (2010-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://content.healthaffairs.org/content/29/5/1037\">\"The Growing Financial Burden Of Health Care: National And State Trends, 2001\u20132006\"</a>. <i>Health Affairs</i>. <b>29</b> (5): 1037\u20131044. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1377/hlthaff.2009.0493\">10.1377/hlthaff.2009.0493</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0278-2715\">0278-2715</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/20338908\">20338908</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=The+Growing+Financial+Burden+Of+Health+Care%3A+National+And+State+Trends%2C+2001%E2%80%932006&amp;rft.volume=29&amp;rft.issue=5&amp;rft.pages=1037-1044&amp;rft.date=2010-05-01&amp;rft.issn=0278-2715&amp;rft_id=info%3Apmid%2F20338908&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.2009.0493&amp;rft.aulast=Cunningham&amp;rft.aufirst=Peter+J.&amp;rft_id=http%3A%2F%2Fcontent.healthaffairs.org%2Fcontent%2F29%2F5%2F1037&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Flaherty, Mary Pat; Gaul, Gilbert M. (2003-10-23). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.washingtonpost.com/archive/politics/2003/10/23/millions-of-americans-look-outside-us-for-drugs/8bfeb294-b1b2-4be5-bb4b-0764d1e899d3/\">\"Millions of Americans Look Outside U.S. for Drugs\"</a>. <i>The Washington Post</i>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0190-8286\">0190-8286</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Washington+Post&amp;rft.atitle=Millions+of+Americans+Look+Outside+U.S.+for+Drugs&amp;rft.date=2003-10-23&amp;rft.issn=0190-8286&amp;rft.aulast=Flaherty&amp;rft.aufirst=Mary+Pat&amp;rft.au=Gaul%2C+Gilbert+M.&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Farchive%2Fpolitics%2F2003%2F10%2F23%2Fmillions-of-americans-look-outside-us-for-drugs%2F8bfeb294-b1b2-4be5-bb4b-0764d1e899d3%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-20\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Morgan, Steven; Hurley, Jeremiah (2004-03-16). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cmaj.ca/content/170/6/945\">\"Internet pharmacy: prices on the up-and-up\"</a>. <i>Canadian Medical Association Journal</i>. <b>170</b> (6): 945\u2013946. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1503/cmaj.104001\">10.1503/cmaj.104001</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0820-3946\">0820-3946</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC359422\">359422</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/15023915\">15023915</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Canadian+Medical+Association+Journal&amp;rft.atitle=Internet+pharmacy%3A+prices+on+the+up-and-up&amp;rft.volume=170&amp;rft.issue=6&amp;rft.pages=945-946&amp;rft.date=2004-03-16&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC359422&amp;rft.issn=0820-3946&amp;rft_id=info%3Apmid%2F15023915&amp;rft_id=info%3Adoi%2F10.1503%2Fcmaj.104001&amp;rft.aulast=Morgan&amp;rft.aufirst=Steven&amp;rft.au=Hurley%2C+Jeremiah&amp;rft_id=http%3A%2F%2Fwww.cmaj.ca%2Fcontent%2F170%2F6%2F945&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://kff.org/health-costs/press-release/poll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem/\">\"Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2015-11-27</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Poll+Finds+Nearly+Three+Quarters+of+Americans+Say+Prescription+Drug+Costs+Are+Unreasonable%2C+and+Most+Blame+Drug+Makers+Rather+Than+Insurers+for+the+Problem&amp;rft_id=http%3A%2F%2Fkff.org%2Fhealth-costs%2Fpress-release%2Fpoll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:2-22\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:2_22-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:2_22-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:2_22-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kennedy, Jae; Morgan, Steve (2009). <a rel=\"nofollow\" class=\"external text\" href=\"http://linkinghub.elsevier.com/retrieve/pii/S0149291809000204\">\"Cost-related prescription nonadherence in the united states and Canada: A system-level comparison using the 2007 international health policy survey in seven countries\"</a>. <i>Clinical Therapeutics</i>. <b>31</b> (1): 213\u2013219. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.clinthera.2009.01.006\">10.1016/j.clinthera.2009.01.006</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Therapeutics&amp;rft.atitle=Cost-related+prescription+nonadherence+in+the+united+states+and+Canada%3A+A+system-level+comparison+using+the+2007+international+health+policy+survey+in+seven+countries&amp;rft.volume=31&amp;rft.issue=1&amp;rft.pages=213-219&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinthera.2009.01.006&amp;rft.aulast=Kennedy&amp;rft.aufirst=Jae&amp;rft.au=Morgan%2C+Steve&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0149291809000204&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:3-23\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:3_23-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:3_23-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:3_23-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:3_23-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Kennedy, Jae; Morgan, Steve (2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://linkinghub.elsevier.com/retrieve/pii/S0149291806001718\">\"A cross-national study of prescription nonadherence due to cost: Data from the joint Canada-United States survey of health\"</a>. <i>Clinical Therapeutics</i>. <b>28</b> (8): 1217\u20131224. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.clinthera.2006.07.009\">10.1016/j.clinthera.2006.07.009</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Therapeutics&amp;rft.atitle=A+cross-national+study+of+prescription+nonadherence+due+to+cost%3A+Data+from+the+joint+Canada-United+States+survey+of+health&amp;rft.volume=28&amp;rft.issue=8&amp;rft.pages=1217-1224&amp;rft.date=2006&amp;rft_id=info%3Adoi%2F10.1016%2Fj.clinthera.2006.07.009&amp;rft.aulast=Kennedy&amp;rft.aufirst=Jae&amp;rft.au=Morgan%2C+Steve&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0149291806001718&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://medicare.com/medicare-part-d/coverage-gap-donut-hole-made-simple/\">\"Medicare Part D Coverage Gap (\"Donut Hole\")\"</a>. <i>medicare.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2016-10-22</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=medicare.com&amp;rft.atitle=Medicare+Part+D+Coverage+Gap+%28%22Donut+Hole%22%29&amp;rft_id=https%3A%2F%2Fmedicare.com%2Fmedicare-part-d%2Fcoverage-gap-donut-hole-made-simple%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Manchikanti, Laxmaiah; Caraway, David; Parr, Allan; Fellows, Bert; Hirsch, Joshua (2011). \"Patient Protection and Affordable Care Act of 2010: Reforming the Health Care Reform for the New Decade\". <i>Pain Physician</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pain+Physician&amp;rft.atitle=Patient+Protection+and+Affordable+Care+Act+of+2010%3A+Reforming+the+Health+Care+Reform+for+the+New+Decade&amp;rft.date=2011&amp;rft.aulast=Manchikanti&amp;rft.aufirst=Laxmaiah&amp;rft.au=Caraway%2C+David&amp;rft.au=Parr%2C+Allan&amp;rft.au=Fellows%2C+Bert&amp;rft.au=Hirsch%2C+Joshua&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.cdc.gov/nchs/data/databriefs/db184.htm\">\"Products - Data Briefs - Number 184 - January 2015\"</a>. <i>www.cdc.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-04-10</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.cdc.gov&amp;rft.atitle=Products+-+Data+Briefs+-+Number+184+-+January+2015&amp;rft_id=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Fdatabriefs%2Fdb184.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hsu, John; Price, Mary; Huang, Jie; Brand, Richard; Fung, Vicki; Hui, Rita; Fireman, Bruce; Newhouse, Joseph P.; Selby, Joseph V. (2006-06-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1056/NEJMsa054436\">\"Unintended Consequences of Caps on Medicare Drug Benefits\"</a>. <i>New England Journal of Medicine</i>. <b>354</b> (22): 2349\u20132359. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/nejmsa054436\">10.1056/nejmsa054436</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0028-4793\">0028-4793</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/16738271\">16738271</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Unintended+Consequences+of+Caps+on+Medicare+Drug+Benefits&amp;rft.volume=354&amp;rft.issue=22&amp;rft.pages=2349-2359&amp;rft.date=2006-06-01&amp;rft.issn=0028-4793&amp;rft_id=info%3Apmid%2F16738271&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmsa054436&amp;rft.aulast=Hsu&amp;rft.aufirst=John&amp;rft.au=Price%2C+Mary&amp;rft.au=Huang%2C+Jie&amp;rft.au=Brand%2C+Richard&amp;rft.au=Fung%2C+Vicki&amp;rft.au=Hui%2C+Rita&amp;rft.au=Fireman%2C+Bruce&amp;rft.au=Newhouse%2C+Joseph+P.&amp;rft.au=Selby%2C+Joseph+V.&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1056%2FNEJMsa054436&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chandra, Amitabh; Gruber, Jonathan; McKnight, Robin (2010). \"Patient Cost-Sharing and Hospitalization Offsets in the Elderly\". <i>The American Economic Review</i>. <b>100</b> (1): 193\u2013213. <a href=\"/wiki/JSTOR\" title=\"JSTOR\">JSTOR</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.jstor.org/stable/27804926\">27804926</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+American+Economic+Review&amp;rft.atitle=Patient+Cost-Sharing+and+Hospitalization+Offsets+in+the+Elderly&amp;rft.volume=100&amp;rft.issue=1&amp;rft.pages=193-213&amp;rft.date=2010&amp;rft_id=%2F%2Fwww.jstor.org%2Fstable%2F27804926&amp;rft.aulast=Chandra&amp;rft.aufirst=Amitabh&amp;rft.au=Gruber%2C+Jonathan&amp;rft.au=McKnight%2C+Robin&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Alexander GC, Long C, Kaestner R. (December 1, 2016). \"Association Between Prescription Drug Insurance and Hospitalization Among Medicare Beneficiaries\". <i>Medical Care Research and Review</i>. <b>75</b>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Care+Research+and+Review&amp;rft.atitle=Association+Between+Prescription+Drug+Insurance+and+Hospitalization+Among+Medicare+Beneficiaries&amp;rft.volume=75&amp;rft.date=2016-12-01&amp;rft.au=Alexander+GC%2C+Long+C%2C+Kaestner+R.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Multiple names: authors list (<a href=\"/wiki/Category:CS1_maint:_Multiple_names:_authors_list\" title=\"Category:CS1 maint: Multiple names: authors list\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-lancet15-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-lancet15_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Jaffe, Susan (28 November 2015). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2901098-3/fulltext\">\"USA grapples with high drug costs\"</a>. <i>The Lancet</i>. <b>386</b> (10009): 2127\u20132128. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2815%2901098-3\">10.1016/S0140-6736(15)01098-3</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26638951\">26638951</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=USA+grapples+with+high+drug+costs&amp;rft.volume=386&amp;rft.issue=10009&amp;rft.pages=2127-2128&amp;rft.date=2015-11-28&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2815%2901098-3&amp;rft_id=info%3Apmid%2F26638951&amp;rft.aulast=Jaffe&amp;rft.aufirst=Susan&amp;rft_id=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252815%252901098-3%2Ffulltext&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\">Ambrish Singh. 2017. Transparency in Drug Pricing - Is it a New Trend in Making? [Online] Available at: <a rel=\"nofollow\" class=\"external free\" href=\"https://www.linkedin.com/pulse/transparency-drug-pricing-new-trend-making-ambrish-singh/\">https://www.linkedin.com/pulse/transparency-drug-pricing-new-trend-making-ambrish-singh/</a>. [Accessed 25 September 2017].</span>\n</li>\n<li id=\"cite_note-:4-32\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:4_32-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:4_32-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.iphandbook.org/handbook/ch10/p09/\">\"The Interface of Patents with the Regulatory Drug Approval Process and How Resulting Interplay Can Affect Market Entry\"</a>. <i>www.iphandbook.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.iphandbook.org&amp;rft.atitle=The+Interface+of+Patents+with+the+Regulatory+Drug+Approval+Process+and+How+Resulting+Interplay+Can+Affect+Market+Entry&amp;rft_id=http%3A%2F%2Fwww.iphandbook.org%2Fhandbook%2Fch10%2Fp09%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:6-33\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:6_33-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:6_33-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Ulwik, James (2015). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.luc.edu/media/lucedu/law/centers/antitrust/pdfs/publications/newsviews/Ulwick%20Pay-to-Delay%20-%20Antitrust%20NewsViews%20-%20JAU%20Edits%204%2023%202015.pdf\">\"Pay-to-Delay: How to Prevent Competition and Get Away With It\"</a> <span style=\"font-size:85%;\">(PDF)</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pay-to-Delay%3A+How+to+Prevent+Competition+and+Get+Away+With+It&amp;rft.date=2015&amp;rft.aulast=Ulwik&amp;rft.aufirst=James&amp;rft_id=http%3A%2F%2Fwww.luc.edu%2Fmedia%2Flucedu%2Flaw%2Fcenters%2Fantitrust%2Fpdfs%2Fpublications%2Fnewsviews%2FUlwick%2520Pay-to-Delay%2520-%2520Antitrust%2520NewsViews%2520-%2520JAU%2520Edits%25204%252023%25202015.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-kaiser-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-kaiser_34-0\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://kff.org/health-costs/press-release/poll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem/\">Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem</a> Kaiser Family Foundation. 16 June 2015, accessed 27 November 2015</span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Erik Sherman (October 7, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cbsnews.com/news/higher-drug-prices-support-profits-not-research/\">\"The real reason U.S. drug prices are so high\"</a>. <i>CBS news</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CBS+news&amp;rft.atitle=The+real+reason+U.S.+drug+prices+are+so+high&amp;rft.date=2015-10-07&amp;rft.au=Erik+Sherman&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fhigher-drug-prices-support-profits-not-research%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-greene-36\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-greene_36-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-greene_36-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-greene_36-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Greene, Jeremy A.; Anderson, Gerard; Sharfstein, Joshua M. (2016). \"Role of the FDA in Affordability of Off-Patent Pharmaceuticals\". <i>Journal of the American Medical Association</i>. <b>31</b>: 461\u2013462. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2015.18720\">10.1001/jama.2015.18720</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+the+American+Medical+Association&amp;rft.atitle=Role+of+the+FDA+in+Affordability+of+Off-Patent+Pharmaceuticals&amp;rft.volume=31&amp;rft.pages=461-462&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2015.18720&amp;rft.aulast=Greene&amp;rft.aufirst=Jeremy+A.&amp;rft.au=Anderson%2C+Gerard&amp;rft.au=Sharfstein%2C+Joshua+M.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"font-size:0.95em; font-size:90%; color:#555\">(subscription required)</span></span>\n</li>\n<li id=\"cite_note-Cahn-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Cahn_37-0\">^</a></b></span> <span class=\"reference-text\">Linda Cahn <a rel=\"nofollow\" class=\"external text\" href=\"http://www.managedcaremag.com/archives/1009/1009.cahn_generic.html\">When Is a Brand a Generic? In a Contract With a PBM</a> Managed Care, September 2010. accessed 2 December 2015.</span>\n</li>\n<li id=\"cite_note-usa14-38\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-usa14_38-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-usa14_38-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Jayne O'Donnell (3 March 2014). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.usatoday.com/story/money/personalfinance/2014/03/03/pharmacy-benefit-managers-healthcare-costs-savings/5495317/\">\"Do drug benefit managers reduce health costs?\"</a>. <i>USA Today</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">1 August</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=USA+Today&amp;rft.atitle=Do+drug+benefit+managers+reduce+health+costs%3F&amp;rft.date=2014-03-03&amp;rft.au=Jayne+O%27Donnell&amp;rft_id=https%3A%2F%2Fwww.usatoday.com%2Fstory%2Fmoney%2Fpersonalfinance%2F2014%2F03%2F03%2Fpharmacy-benefit-managers-healthcare-costs-savings%2F5495317%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-forbes-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-forbes_39-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Matthew Herper (10 May 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.forbes.com/sites/matthewherper/2012/05/10/why-astrazeneca-gives-insurers-60-discounts-on-nexiums-list-price/\">\"Inside The Secret World Of Drug Company Rebates\"</a>. <i>Forbes</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=Inside+The+Secret+World+Of+Drug+Company+Rebates&amp;rft.date=2012-05-10&amp;rft.au=Matthew+Herper&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2012%2F05%2F10%2Fwhy-astrazeneca-gives-insurers-60-discounts-on-nexiums-list-price%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\">Matthew Herper <a rel=\"nofollow\" class=\"external text\" href=\"https://www.forbes.com/sites/matthewherper/2012/03/19/how-to-charge-1-6-million-for-a-new-drug-and-get-away-with-it/\">How To Charge $1.6 Million For a New Drug And Get Away With It. Forbes, Mar 19, 2012, accessed 2 December 2015</a></span>\n</li>\n<li id=\"cite_note-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-41\">^</a></b></span> <span class=\"reference-text\">Ed Silverman <a rel=\"nofollow\" class=\"external text\" href=\"https://blogs.wsj.com/pharmalot/2014/09/29/high-prices-for-orphan-drug-can-be-sustained-a-payer-survey-shows/\">High Prices for Orphan Drug can be Sustained, a Payer Survey Shows.</a> WSJ, 29 September 2014, accessed 2 December 2015</span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Silverman, Ed (2 March 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.statnews.com/pharmalot/2016/03/02/fda-generic-drugs/\">\"FDA still struggling with backlog of generic drug applications\"</a>. <a href=\"/wiki/Stat_(website)\" title=\"Stat (website)\">Stat (website)</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">17 August</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+still+struggling+with+backlog+of+generic+drug+applications&amp;rft.date=2016-03-02&amp;rft.aulast=Silverman&amp;rft.aufirst=Ed&amp;rft_id=https%3A%2F%2Fwww.statnews.com%2Fpharmalot%2F2016%2F03%2F02%2Ffda-generic-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lee, Chia-Ying; Chen, Xiaohan; Romanelli, Robert J.; Segal, Jodi B. (2016-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org/10.1186/s40545-016-0079-1\">\"Forces influencing generic drug development in the United States: a narrative review\"</a>. <i>Journal of Pharmaceutical Policy and Practice</i>. <b>9</b>: 26. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1186/s40545-016-0079-1\">10.1186/s40545-016-0079-1</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/2052-3211\">2052-3211</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5034442\">5034442</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27688886\">27688886</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pharmaceutical+Policy+and+Practice&amp;rft.atitle=Forces+influencing+generic+drug+development+in+the+United+States%3A+a+narrative+review&amp;rft.volume=9&amp;rft.pages=26&amp;rft.date=2016-01-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5034442&amp;rft.issn=2052-3211&amp;rft_id=info%3Apmid%2F27688886&amp;rft_id=info%3Adoi%2F10.1186%2Fs40545-016-0079-1&amp;rft.aulast=Lee&amp;rft.aufirst=Chia-Ying&amp;rft.au=Chen%2C+Xiaohan&amp;rft.au=Romanelli%2C+Robert+J.&amp;rft.au=Segal%2C+Jodi+B.&amp;rft_id=https%3A%2F%2Fdx.doi.org%2F10.1186%2Fs40545-016-0079-1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-44\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Morgenson, Gretchen (2017-04-14). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2017/04/14/business/lannett-drug-price-hike-bedrosian.html\">\"Defiant, Generic Drug Maker Continues to Raise Prices\"</a>. <i>The New York Times</i>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0362-4331\">0362-4331</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Defiant%2C+Generic+Drug+Maker+Continues+to+Raise+Prices&amp;rft.date=2017-04-14&amp;rft.issn=0362-4331&amp;rft.aulast=Morgenson&amp;rft.aufirst=Gretchen&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2017%2F04%2F14%2Fbusiness%2Flannett-drug-price-hike-bedrosian.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-45\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs\">\"Expanding the Use of Generic Drugs\"</a>. <i>ASPE</i>. 2015-06-13<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ASPE&amp;rft.atitle=Expanding+the+Use+of+Generic+Drugs&amp;rft.date=2015-06-13&amp;rft_id=https%3A%2F%2Faspe.hhs.gov%2Fbasic-report%2Fexpanding-use-generic-drugs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-46\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals\">\"FDA Fees On Industry Haven't Fixed Delays In Generic Drug Approvals\"</a>. <i>NPR.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NPR.org&amp;rft.atitle=FDA+Fees+On+Industry+Haven%27t+Fixed+Delays+In+Generic+Drug+Approvals&amp;rft_id=https%3A%2F%2Fwww.npr.org%2Fsections%2Fhealth-shots%2F2016%2F09%2F01%2F492235796%2Ffda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:8-47\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:8_47-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:8_47-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:8_47-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Research, Center for Drug Evaluation and. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/forindustry/userfees/genericdruguserfees/default.htm\">\"Generic Drug User Fee Amendments of 2012\"</a>. <i>www.fda.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Generic+Drug+User+Fee+Amendments+of+2012&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fforindustry%2Fuserfees%2Fgenericdruguserfees%2Fdefault.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:7-48\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:7_48-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:7_48-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.cbsnews.com/news/epipen-price-hike-controversy-mylan-ceo-heather-bresch-speaks-out/\">\"Mylan CEO on EpiPen drug price controversy: \"I get the outrage<span style=\"padding-right:0.2em;\">\"</span>\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-05-01</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan+CEO+on+EpiPen+drug+price+controversy%3A+%22I+get+the+outrage%22&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fepipen-price-hike-controversy-mylan-ceo-heather-bresch-speaks-out%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-49\">^</a></b></span> <span class=\"reference-text\">FDA. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/UCM451179.pdf.\">FY 2014 Performance Report to the President and Congress for the Generic Drug User Fee Amendments.</a> FDA User Fee Reports, Accessed 4 January 2015.</span>\n</li>\n<li id=\"cite_note-wood-50\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-wood_50-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-wood_50-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://1.usa.gov/1POUpcB\">Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) Testimony of Janet Woodcock, M.D.Director, Center for Drug Evaluation and Research U.S. Food and Drug Administration</a> Before the Committee on Health, Education, Labor and Pensions. United States Senate, 18 pages, January 28, 2016.</span>\n</li>\n<li id=\"cite_note-51\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-51\">^</a></b></span> <span class=\"reference-text\">Nature Reviews Drug Discovery, 2004 (3), 711\u2013716.</span>\n</li>\n<li id=\"cite_note-SmithandODonnell-52\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SmithandODonnell_52-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SmithandODonnell_52-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=-DgAe57FAGcC&amp;pg=PA422&amp;lpg=PA422&amp;dq=%22united+states%22+canada+drug+development&amp;source=bl&amp;ots=8OG3m9xPqW&amp;sig=OBf-c8QRoKkvXfoF6wVUiAb_K4Y&amp;hl=en&amp;ei=LSqhS_TQMIWglAeEk4TfDQ&amp;sa=X&amp;oi=book_result&amp;ct=result&amp;resnum=22&amp;ved=0CFwQ6AEwFQ\">The Process of New Drug Discovery and Development</a> Second Edition, Charles G. Smith and James T. O'Donnell, Taylor &amp; Francis, 2006, <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/0849327792\" title=\"Special:BookSources/0849327792\">0849327792</a>, 9780849327797 688 pages, published by Informa Healthcare</span>\n</li>\n<li id=\"cite_note-53\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-53\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Herper, Matthew. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/\">\"The Truly Staggering Cost Of Inventing New Drugs\"</a>. Forbes<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">29 March</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Truly+Staggering+Cost+Of+Inventing+New+Drugs&amp;rft.aulast=Herper&amp;rft.aufirst=Matthew&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fmatthewherper%2F2012%2F02%2F10%2Fthe-truly-staggering-cost-of-inventing-new-drugs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-54\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-54\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://archive.psc-cuny.org/drugprices.htm\">Why Are Drug Prices So High?</a>, PSC/<a href=\"/wiki/City_University_of_New_York\" title=\"City University of New York\">City University of New York</a></span>\n</li>\n<li id=\"cite_note-:0-55\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_55-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_55-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Brandon Kramer and Michael Shally-Jensen. <a rel=\"nofollow\" class=\"external text\" href=\"https://books.google.com/books?id=BjKWfAz0tx4C&amp;lpg=PA273&amp;dq=Prescription%20Drug%20costs%20Brandon%20Kramer%20%20and%20Michael%20Shally-Jensen&amp;pg=PA273#v=onepage&amp;q=Prescription%20Drug%20costs%20Brandon%20Kramer%20%20and%20Michael%20Shally-Jensen&amp;f=false\">Prescription Drug costs</a>. pp 273-283. in: Encyclopedia of Contemporary American Social Issues 4 volumes, ABC-CLIO, December 22, 2010, Social Science, 1707 pages,  Santa Barbara</span>\n</li>\n<li id=\"cite_note-56\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-56\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Charles L. Hooper; David R. Henderson (2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://object.cato.org/sites/cato.org/files/serials/files/regulation/2016/4/regulation-v39n1-2.pdf\">\"Want Cheaper Drugs\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Regulation</i>. Cato Institute.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Regulation&amp;rft.atitle=Want+Cheaper+Drugs&amp;rft.date=2016&amp;rft.au=Charles+L.+Hooper&amp;rft.au=David+R.+Henderson&amp;rft_id=https%3A%2F%2Fobject.cato.org%2Fsites%2Fcato.org%2Ffiles%2Fserials%2Ffiles%2Fregulation%2F2016%2F4%2Fregulation-v39n1-2.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-57\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-57\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Jeanne Whalen (December 1, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.wsj.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481\">\"Why the U.S. Pays More than Other Countries for Drugs\"</a>. <i>Wall Street Journal</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Why+the+U.S.+Pays+More+than+Other+Countries+for+Drugs&amp;rft.date=2015-12-01&amp;rft.au=Jeanne+Whalen&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fwhy-the-u-s-pays-more-than-other-countries-for-drugs-1448939481&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:9-58\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:9_58-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:9_58-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://catalyst.nejm.org/who-has-the-power-to-cut-drug-prices/\">\"Who Has the Power to Cut Drug Prices? - NEJM Catalyst\"</a>. <i>NEJM Catalyst</i>. 2016-01-13<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-10-30</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NEJM+Catalyst&amp;rft.atitle=Who+Has+the+Power+to+Cut+Drug+Prices%3F+-+NEJM+Catalyst&amp;rft.date=2016-01-13&amp;rft_id=https%3A%2F%2Fcatalyst.nejm.org%2Fwho-has-the-power-to-cut-drug-prices%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-59\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-59\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Office of Pharmacy Affairs (n.d.). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.hrsa.gov/opa/\">\"340B Drug Pricing Program\"</a>. Health Resources and Services Administration<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 December</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=340B+Drug+Pricing+Program&amp;rft.pub=Health+Resources+and+Services+Administration&amp;rft.au=Office+of+Pharmacy+Affairs&amp;rft_id=http%3A%2F%2Fwww.hrsa.gov%2Fopa%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:10-60\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:10_60-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:10_60-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.consumerreports.org/drugs/6-tips-for-finding-the-best-prescription-drug-prices/\">\"Save Money on Meds: 9 Tips for Finding the Best Prescription Drug Prices\"</a>. <i>Consumer Reports</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-10-30</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Consumer+Reports&amp;rft.atitle=Save+Money+on+Meds%3A+9+Tips+for+Finding+the+Best+Prescription+Drug+Prices&amp;rft_id=https%3A%2F%2Fwww.consumerreports.org%2Fdrugs%2F6-tips-for-finding-the-best-prescription-drug-prices%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-61\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-61\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.npr.org/sections/health-shots/2015/09/16/440612238/how-to-save-money-on-prescription-drugs-insured-or-not\">\"How To Save Money On Prescription Drugs, Insured Or Not\"</a>. <i>NPR.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-10-30</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NPR.org&amp;rft.atitle=How+To+Save+Money+On+Prescription+Drugs%2C+Insured+Or+Not&amp;rft_id=https%3A%2F%2Fwww.npr.org%2Fsections%2Fhealth-shots%2F2015%2F09%2F16%2F440612238%2Fhow-to-save-money-on-prescription-drugs-insured-or-not&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-62\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-62\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Starner CI, Alexander GC, Bowen K, Qui Y, Wickersham P, Gleason PP. (Oct 2014). \"Specialty Drug Coupons Lower Out-of-pocket Costs and May Improve Adherence at the Risk of Increasing Premiums\". <i>Health Affairs</i>. <b>33</b>: 1761\u20131769.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Specialty+Drug+Coupons+Lower+Out-of-pocket+Costs+and+May+Improve+Adherence+at+the+Risk+of+Increasing+Premiums&amp;rft.volume=33&amp;rft.pages=1761-1769&amp;rft.date=2014-10&amp;rft.au=Starner+CI%2C+Alexander+GC%2C+Bowen+K%2C+Qui+Y%2C+Wickersham+P%2C+Gleason+PP.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Multiple names: authors list (<a href=\"/wiki/Category:CS1_maint:_Multiple_names:_authors_list\" title=\"Category:CS1 maint: Multiple names: authors list\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-63\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-63\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Daubresse, Matthew; Andersen, Martin; Riggs, Kevin R.; Alexander, G. Caleb (2017-01-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://doi.wiley.com/10.1002/phar.1802\">\"Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study\"</a>. <i>Pharmacotherapy</i>. <b>37</b> (1): 12\u201324. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1002/phar.1802\">10.1002/phar.1802</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1875-9114\">1875-9114</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharmacotherapy&amp;rft.atitle=Effect+of+Prescription+Drug+Coupons+on+Statin+Utilization+and+Expenditures%3A+A+Retrospective+Cohort+Study&amp;rft.volume=37&amp;rft.issue=1&amp;rft.pages=12-24&amp;rft.date=2017-01-01&amp;rft_id=info%3Adoi%2F10.1002%2Fphar.1802&amp;rft.issn=1875-9114&amp;rft.aulast=Daubresse&amp;rft.aufirst=Matthew&amp;rft.au=Andersen%2C+Martin&amp;rft.au=Riggs%2C+Kevin+R.&amp;rft.au=Alexander%2C+G.+Caleb&amp;rft_id=http%3A%2F%2Fdoi.wiley.com%2F10.1002%2Fphar.1802&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-64\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-64\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Grande, David (2012-06-13). <a rel=\"nofollow\" class=\"external text\" href=\"https://jamanetwork.com/journals/jama/fullarticle/1182868\">\"The Cost of Drug Coupons\"</a>. <i>JAMA</i>. <b>307</b> (22): 2375\u20132376. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/jama.2012.5603\">10.1001/jama.2012.5603</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0098-7484\">0098-7484</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=JAMA&amp;rft.atitle=The+Cost+of+Drug+Coupons&amp;rft.volume=307&amp;rft.issue=22&amp;rft.pages=2375-2376&amp;rft.date=2012-06-13&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2012.5603&amp;rft.issn=0098-7484&amp;rft.aulast=Grande&amp;rft.aufirst=David&amp;rft_id=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F1182868&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-65\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-65\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Ross, Joseph S.; Kesselheim, Aaron S. (2013-09-25). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.nejm.org/doi/10.1056/NEJMp1301993\">\"Prescription-Drug Coupons \u2014 No Such Thing as a Free Lunch\"</a>. <i>New England Journal of Medicine</i>. <b>369</b> (13): 1188\u20131189. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/nejmp1301993\">10.1056/nejmp1301993</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Prescription-Drug+Coupons+%E2%80%94+No+Such+Thing+as+a+Free+Lunch&amp;rft.volume=369&amp;rft.issue=13&amp;rft.pages=1188-1189&amp;rft.date=2013-09-25&amp;rft_id=info%3Adoi%2F10.1056%2Fnejmp1301993&amp;rft.aulast=Ross&amp;rft.aufirst=Joseph+S.&amp;rft.au=Kesselheim%2C+Aaron+S.&amp;rft_id=http%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMp1301993&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:11-66\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:11_66-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:11_66-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\">Research, Center for Drug Evaluation and. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs/UCM167991.htm\">\"Generic Drugs - Generic Drug Facts\"</a>. <i>www.fda.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-10-30</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=Generic+Drugs+-+Generic+Drug+Facts&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresourcesforyou%2Fconsumers%2Fbuyingusingmedicinesafely%2Fgenericdrugs%2FUCM167991.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:02-67\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:02_67-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:02_67-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\">Schoonveld, Ed (2015). <i>The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation</i>. Gower Publishing, Ltd. pp.&#160;73\u201386. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/1472438825\" title=\"Special:BookSources/1472438825\">1472438825</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=The+Price+of+Global+Health%3A+Drug+Pricing+Strategies+to+Balance+Patient+Access+and+the+Funding+of+Innovation&amp;rft.pages=73-86&amp;rft.pub=Gower+Publishing%2C+Ltd&amp;rft.date=2015&amp;rft.isbn=1472438825&amp;rft.aulast=Schoonveld&amp;rft.aufirst=Ed&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-68\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-68\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mehrez, Abraham; Gafni, Amiram (1989). <a rel=\"nofollow\" class=\"external text\" href=\"http://journals.sagepub.com/doi/pdf/10.1177/0272989X8900900209\">\"Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents\"</a>. <i>Medical Decision Making</i>. <b>9</b> (2): 142\u2013149. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1177/0272989x8900900209\">10.1177/0272989x8900900209</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Decision+Making&amp;rft.atitle=Quality-adjusted+Life+Years%2C+Utility+Theory%2C+and+Healthy-years+Equivalents&amp;rft.volume=9&amp;rft.issue=2&amp;rft.pages=142-149&amp;rft.date=1989&amp;rft_id=info%3Adoi%2F10.1177%2F0272989x8900900209&amp;rft.aulast=Mehrez&amp;rft.aufirst=Abraham&amp;rft.au=Gafni%2C+Amiram&amp;rft_id=http%3A%2F%2Fjournals.sagepub.com%2Fdoi%2Fpdf%2F10.1177%2F0272989X8900900209&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-69\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-69\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Blayney, Douglas W.; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell; Langdon, Robert; Lyman, Gary H. (2016-08-20). <a rel=\"nofollow\" class=\"external text\" href=\"http://ascopubs.org/doi/10.1200/JCO.2016.68.2518\">\"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received\"</a>. <i>Journal of Clinical Oncology</i>. <b>34</b> (24): 2925\u20132934. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1200/JCO.2016.68.2518\">10.1200/JCO.2016.68.2518</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0732-183X\">0732-183X</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=Updating+the+American+Society+of+Clinical+Oncology+Value+Framework%3A+Revisions+and+Reflections+in+Response+to+Comments+Received&amp;rft.volume=34&amp;rft.issue=24&amp;rft.pages=2925-2934&amp;rft.date=2016-08-20&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2016.68.2518&amp;rft.issn=0732-183X&amp;rft.aulast=Schnipper&amp;rft.aufirst=Lowell+E.&amp;rft.au=Davidson%2C+Nancy+E.&amp;rft.au=Wollins%2C+Dana+S.&amp;rft.au=Blayney%2C+Douglas+W.&amp;rft.au=Dicker%2C+Adam+P.&amp;rft.au=Ganz%2C+Patricia+A.&amp;rft.au=Hoverman%2C+J.+Russell&amp;rft.au=Langdon%2C+Robert&amp;rft.au=Lyman%2C+Gary+H.&amp;rft_id=http%3A%2F%2Fascopubs.org%2Fdoi%2F10.1200%2FJCO.2016.68.2518&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:12-70\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:12_70-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:12_70-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Tyne, Courtney; Blayney, Douglas W.; Blum, Diane; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell (2015-08-10). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427\">\"American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options\"</a>. <i>Journal of Clinical Oncology</i>. <b>33</b> (23): 2563\u20132577. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1200/JCO.2015.61.6706\">10.1200/JCO.2015.61.6706</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427\">5015427</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26101248\">26101248</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=American+Society+of+Clinical+Oncology+Statement%3A+A+Conceptual+Framework+to+Assess+the+Value+of+Cancer+Treatment+Options&amp;rft.volume=33&amp;rft.issue=23&amp;rft.pages=2563-2577&amp;rft.date=2015-08-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5015427&amp;rft_id=info%3Apmid%2F26101248&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2015.61.6706&amp;rft.aulast=Schnipper&amp;rft.aufirst=Lowell+E.&amp;rft.au=Davidson%2C+Nancy+E.&amp;rft.au=Wollins%2C+Dana+S.&amp;rft.au=Tyne%2C+Courtney&amp;rft.au=Blayney%2C+Douglas+W.&amp;rft.au=Blum%2C+Diane&amp;rft.au=Dicker%2C+Adam+P.&amp;rft.au=Ganz%2C+Patricia+A.&amp;rft.au=Hoverman%2C+J.+Russell&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5015427&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-71\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-71\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cherny, N. I.; Dafni, U.; Bogaerts, J.; Latino, N. J.; Pentheroudakis, G.; Douillard, J.-Y.; Tabernero, J.; Zielinski, C.; Piccart, M. J. (2017-09-04). <a rel=\"nofollow\" class=\"external text\" href=\"http://academic.oup.com/annonc/article/28/10/2340/4102112/ESMOMagnitude-of-Clinical-Benefit-Scale-version-11\">\"ESMO-Magnitude of Clinical Benefit Scale version 1.1\"</a>. <i>Annals of Oncology</i>. <b>28</b> (10): 2340\u20132366. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/annonc/mdx310\">10.1093/annonc/mdx310</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0923-7534\">0923-7534</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=ESMO-Magnitude+of+Clinical+Benefit+Scale+version+1.1&amp;rft.volume=28&amp;rft.issue=10&amp;rft.pages=2340-2366&amp;rft.date=2017-09-04&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdx310&amp;rft.issn=0923-7534&amp;rft.aulast=Cherny&amp;rft.aufirst=N.+I.&amp;rft.au=Dafni%2C+U.&amp;rft.au=Bogaerts%2C+J.&amp;rft.au=Latino%2C+N.+J.&amp;rft.au=Pentheroudakis%2C+G.&amp;rft.au=Douillard%2C+J.-Y.&amp;rft.au=Tabernero%2C+J.&amp;rft.au=Zielinski%2C+C.&amp;rft.au=Piccart%2C+M.+J.&amp;rft_id=http%3A%2F%2Facademic.oup.com%2Fannonc%2Farticle%2F28%2F10%2F2340%2F4102112%2FESMOMagnitude-of-Clinical-Benefit-Scale-version-11&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:13-72\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-:13_72-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cherny, N. I.; Sullivan, R.; Dafni, U.; Kerst, J. M.; Sobrero, A.; Zielinski, C.; Vries, De; E, E. G.; Piccart, M. J. (2017-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://academic.oup.com/annonc/article/28/11/2901/3062455\">\"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)\"</a>. <i>Annals of Oncology</i>. <b>28</b> (11): 2901\u20132905. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/annonc/mdw258\">10.1093/annonc/mdw258</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0923-7534\">0923-7534</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=A+standardised%2C+generic%2C+validated+approach+to+stratify+the+magnitude+of+clinical+benefit+that+can+be+anticipated+from+anti-cancer+therapies%3A+the+European+Society+for+Medical+Oncology+Magnitude+of+Clinical+Benefit+Scale+%28ESMO-MCBS%29&amp;rft.volume=28&amp;rft.issue=11&amp;rft.pages=2901-2905&amp;rft.date=2017-11-01&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdw258&amp;rft.issn=0923-7534&amp;rft.aulast=Cherny&amp;rft.aufirst=N.+I.&amp;rft.au=Sullivan%2C+R.&amp;rft.au=Dafni%2C+U.&amp;rft.au=Kerst%2C+J.+M.&amp;rft.au=Sobrero%2C+A.&amp;rft.au=Zielinski%2C+C.&amp;rft.au=Vries%2C+De&amp;rft.au=E%2C+E.+G.&amp;rft.au=Piccart%2C+M.+J.&amp;rft_id=https%3A%2F%2Facademic.oup.com%2Fannonc%2Farticle%2F28%2F11%2F2901%2F3062455&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-73\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-73\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Vivot, A.; Jacot, J.; Zeitoun, J.-D.; Ravaud, P.; Crequit, P.; Porcher, R. (2017-05-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://academic.oup.com/annonc/article/28/5/1111/2975592\">\"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015\"</a>. <i>Annals of Oncology</i>. <b>28</b> (5): 1111\u20131116. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1093/annonc/mdx053\">10.1093/annonc/mdx053</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0923-7534\">0923-7534</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=Clinical+benefit%2C+price+and+approval+characteristics+of+FDA-approved+new+drugs+for+treating+advanced+solid+cancer%2C+2000%E2%80%932015&amp;rft.volume=28&amp;rft.issue=5&amp;rft.pages=1111-1116&amp;rft.date=2017-05-01&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdx053&amp;rft.issn=0923-7534&amp;rft.aulast=Vivot&amp;rft.aufirst=A.&amp;rft.au=Jacot%2C+J.&amp;rft.au=Zeitoun%2C+J.-D.&amp;rft.au=Ravaud%2C+P.&amp;rft.au=Crequit%2C+P.&amp;rft.au=Porcher%2C+R.&amp;rft_id=https%3A%2F%2Facademic.oup.com%2Fannonc%2Farticle%2F28%2F5%2F1111%2F2975592&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-74\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-74\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.aging.senate.gov/hearings/sudden-price-spikes-in-off-patent-drugs_perspectives-from-the-front-lines\">Sudden Price Spikes in Off-Patent Drugs: Perspectives from the Front Lines</a> United States Senate Special Committee on Aging, December 9, 2015, retrieved 2 February 2016</span>\n</li>\n<li id=\"cite_note-75\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-75\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Gingery, Derrick (24 July 2017). <a rel=\"nofollow\" class=\"external text\" href=\"https://pink.pharmamedtechbi.com/PS121171/Dems-Better-Deal-Would-Create-Drug-Price-Gouging-Enforcer\">\"Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer<span style=\"padding-right:0.2em;\">'</span>\"</a>. <a href=\"/wiki/OTC_Markets_Group\" title=\"OTC Markets Group\">OTC Markets Group</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">27 July</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dems%27+%27Better+Deal%27+Would+Create+Drug+Price+Gouging+%27Enforcer%27&amp;rft.date=2017-07-24&amp;rft.aulast=Gingery&amp;rft.aufirst=Derrick&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS121171%2FDems-Better-Deal-Would-Create-Drug-Price-Gouging-Enforcer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Senate_Bill_17-76\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Senate_Bill_17_76-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Senate_Bill_17_76-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Senate_Bill_17_76-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://legiscan.com/CA/text/SB17/2017\">\"Senate Bill 17\"</a>. <i>LegiScan</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=LegiScan&amp;rft.atitle=Senate+Bill+17&amp;rft_id=https%3A%2F%2Flegiscan.com%2FCA%2Ftext%2FSB17%2F2017&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-77\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-77\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201720180SB17\">\"SB-17 Health care: prescription drug costs\"</a>. <i>California Legislative Information</i>. 10 September 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">7 August</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=California+Legislative+Information&amp;rft.atitle=SB-17+Health+care%3A+prescription+drug+costs&amp;rft.date=2017-09-10&amp;rft_id=https%3A%2F%2Fleginfo.legislature.ca.gov%2Ffaces%2FbillTextClient.xhtml%3Fbill_id%3D201720180SB17&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-78\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-78\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Menon, Devidas (June 2001). \"Pharmaceutical Cost Control in Canada: Does It Work?\". <i>Health Affairs</i>. <b>20</b>: 1\u201312. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1377/hlthaff.20.3.92\">10.1377/hlthaff.20.3.92</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Health+Affairs&amp;rft.atitle=Pharmaceutical+Cost+Control+in+Canada%3A+Does+It+Work%3F&amp;rft.volume=20&amp;rft.pages=1-12&amp;rft.date=2001-06&amp;rft_id=info%3Adoi%2F10.1377%2Fhlthaff.20.3.92&amp;rft.aulast=Menon&amp;rft.aufirst=Devidas&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-79\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-79\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">The Severyn Group,Inc. (2003). <a rel=\"nofollow\" class=\"external text\" href=\"https://assets.aarp.org/www.aarp.org_/articles/international/proceedingsbooklet.pdf\">\"AARP International Forum on Prescription Drug Policy\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>AARP</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AARP&amp;rft.atitle=AARP+International+Forum+on+Prescription+Drug+Policy&amp;rft.date=2003&amp;rft.au=The+Severyn+Group%2CInc.&amp;rft_id=https%3A%2F%2Fassets.aarp.org%2Fwww.aarp.org_%2Farticles%2Finternational%2Fproceedingsbooklet.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-80\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-80\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9298\">\"Formulary Management\"</a>. <i>Academy of Managed Care Pharmacists</i>. 2015.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Academy+of+Managed+Care+Pharmacists&amp;rft.atitle=Formulary+Management&amp;rft.date=2015&amp;rft_id=http%3A%2F%2Fwww.amcp.org%2FWorkArea%2FDownloadAsset.aspx%3Fid%3D9298&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-81\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-81\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Rabbani, A; Alexander GC (2009). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/pubmed?term=19905039%20\">\"Cost savings associated with filling a 3-month supply of prescription medicines\"</a>. <i>Applied Health Economics and Health Policy</i>. <b>7</b> (4): 255\u2013264. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/bf03256159\">10.1007/bf03256159</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19905039\">19905039</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2011</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Applied+Health+Economics+and+Health+Policy&amp;rft.atitle=Cost+savings+associated+with+filling+a+3-month+supply+of+prescription+medicines.&amp;rft.volume=7&amp;rft.issue=4&amp;rft.pages=255-264&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1007%2Fbf03256159&amp;rft_id=info%3Apmid%2F19905039&amp;rft.aulast=Rabbani&amp;rft.aufirst=A&amp;rft.au=Alexander+GC&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%3Fterm%3D19905039%2520&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-82\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-82\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20170608154237/http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf\">\"American Hospital Association: Drug Policy Recommendations\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>AHA</i>. 2015. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf\">the original</a> <span style=\"font-size:85%;\">(PDF)</span> on 2017-06-08.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=AHA&amp;rft.atitle=American+Hospital+Association%3A+Drug+Policy+Recommendations&amp;rft.date=2015&amp;rft_id=http%3A%2F%2Fwww.aha.org%2Fcontent%2F16%2Faha-drug-policy-recommendations.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-83\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-83\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Love, Robert (2017). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.aarp.org/health/drugs-supplements/info-2017/rx-prescription-drug-pricing.html\">\"Why Our Drugs Cost So Much\"</a>. <i>AARP</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AARP&amp;rft.atitle=Why+Our+Drugs+Cost+So+Much&amp;rft.date=2017&amp;rft.aulast=Love&amp;rft.aufirst=Robert&amp;rft_id=https%3A%2F%2Fwww.aarp.org%2Fhealth%2Fdrugs-supplements%2Finfo-2017%2Frx-prescription-drug-pricing.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-American_Hospital_Association:_Drug_Policy_Recommendations-84\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-American_Hospital_Association:_Drug_Policy_Recommendations_84-0\">^</a></b></span> <span class=\"reference-text\">American Hospital Association</span>\n</li>\n<li id=\"cite_note-85\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-85\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Zullo, Andrew R.; Dore, David D.; Gal\u00e1rraga, Omar (March 2015). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4930104\">\"Development and validation of an index to predict personal prescription drug importation by adults in the United States\"</a>. <i>Journal of Pharmaceutical Health Services Research</i>. <b>6</b> (1): 33\u201341. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/jphs.12088\">10.1111/jphs.12088</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4930104\">4930104</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Pharmaceutical+Health+Services+Research&amp;rft.atitle=Development+and+validation+of+an+index+to+predict+personal+prescription+drug+importation+by+adults+in+the+United+States&amp;rft.volume=6&amp;rft.issue=1&amp;rft.pages=33-41&amp;rft.date=2015-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4930104&amp;rft_id=info%3Adoi%2F10.1111%2Fjphs.12088&amp;rft.aulast=Zullo&amp;rft.aufirst=Andrew+R.&amp;rft.au=Dore%2C+David+D.&amp;rft.au=Gal%C3%A1rraga%2C+Omar&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4930104&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APrescription+drug+prices+in+the+United+States\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Prescription_drug_prices_in_the_United_States&amp;action=edit&amp;section=28\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li>Malcolm Gladwell <a rel=\"nofollow\" class=\"external text\" href=\"http://www.newyorker.com/magazine/2004/10/25/high-prices\">High Prices. How to think about prescription drugs.</a> The New Yorker. October 25, 2004. accessed 28 November 2015.</li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2269\nCached time: 20180913064427\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.760 seconds\nReal time usage: 0.844 seconds\nPreprocessor visited node count: 4295/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 149517/2097152 bytes\nTemplate argument size: 2257/2097152 bytes\nHighest expansion depth: 16/40\nExpensive parser function count: 8/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 105206/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.387/10.000 seconds\nLua memory usage: 5.17 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  718.816      1 -total\n 71.32%  512.677      1 Template:Reflist\n 29.75%  213.866     31 Template:Cite_journal\n 12.77%   91.790     19 Template:Cite_news\n  8.68%   62.363     15 Template:Cite_web\n  6.59%   47.364      1 Template:Lead_too_short\n  5.02%   36.095      3 Template:Fix\n  4.92%   35.351      2 Template:Ambox\n  4.30%   30.927      1 Template:ISBN\n  3.35%   24.061      1 Template:As_of\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:350292-0!canonical and timestamp 20180913064426 and revision id 859315823\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Webarchive_template_wayback_links"},{"sortkey":"","hidden":"","*":"CS1_errors:_missing_author_or_editor"},{"sortkey":"","hidden":"","*":"CS1_maint:_Explicit_use_of_et_al."},{"sortkey":"","hidden":"","*":"CS1_maint:_Multiple_names:_authors_list"},{"sortkey":"","hidden":"","*":"Pages_containing_links_to_subscription-only_content"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Wikipedia_introduction_cleanup_from_March_2016"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"All_pages_needing_cleanup"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Articles_covered_by_WikiProject_Wikify_from_March_2016"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"All_articles_covered_by_WikiProject_Wikify"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Articles_containing_potentially_dated_statements_from_2004"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"All_articles_containing_potentially_dated_statements"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Wikipedia_articles_needing_clarification_from_July_2017"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Articles_needing_the_year_an_event_occurred_from_July_2018"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"NPOV_disputes_from_September_2016"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"All_NPOV_disputes"},{"sortkey":"Prescription Drug Prices In The United States","hidden":"","*":"Wikipedia_articles_needing_page_number_citations_from_February_2016"},{"sortkey":"Prescription Drug Prices In The United States","*":"Pharmaceuticals_policy"},{"sortkey":"Prescription Drug Prices In The United States","*":"Health_policy_in_the_United_States"},{"sortkey":"Prescription Drug Prices In The United States","*":"Healthcare_reform_in_the_United_States"},{"sortkey":"Prescription Drug Prices In The United States","*":"Pharmacy_in_the_United_States"},{"sortkey":"Prescription Drug Prices In The United States","*":"Drug_pricing"},{"sortkey":"Prescription Drug Prices In The United States","*":"Social_problems_in_medicine"}],"links":[{"ns":14,"exists":"","*":"Category:Wikipedia introduction cleanup from March 2016"},{"ns":14,"exists":"","*":"Category:Articles covered by WikiProject Wikify from March 2016"},{"ns":14,"exists":"","*":"Category:Articles containing potentially dated statements from 2004"},{"ns":14,"exists":"","*":"Category:Wikipedia articles needing clarification from July 2017"},{"ns":14,"exists":"","*":"Category:Articles needing the year an event occurred from July 2018"},{"ns":14,"exists":"","*":"Category:NPOV disputes from September 2016"},{"ns":14,"exists":"","*":"Category:Wikipedia articles needing page number citations from February 2016"},{"ns":14,"exists":"","*":"Category:CS1 maint: Explicit use of et al."},{"ns":14,"exists":"","*":"Category:CS1 maint: Multiple names: authors list"},{"ns":1,"exists":"","*":"Talk:Prescription drug prices in the United States"},{"ns":10,"exists":"","*":"Template:POV"},{"ns":0,"exists":"","*":"340B Drug Pricing Program"},{"ns":0,"exists":"","*":"AARP"},{"ns":0,"exists":"","*":"American Enterprise Institute"},{"ns":0,"exists":"","*":"American Society of Clinical Oncology"},{"ns":0,"exists":"","*":"Average wholesale price (pharmaceuticals)"},{"ns":0,"exists":"","*":"Bioequivalence"},{"ns":0,"exists":"","*":"Biosimilar"},{"ns":0,"exists":"","*":"BlueCross BlueShield"},{"ns":0,"exists":"","*":"Brand-name"},{"ns":0,"exists":"","*":"Business strategy"},{"ns":0,"exists":"","*":"CalPERS"},{"ns":0,"exists":"","*":"California"},{"ns":0,"exists":"","*":"Cato Institute"},{"ns":0,"exists":"","*":"Center for Drug Evaluation and Research"},{"ns":0,"exists":"","*":"City University of New York"},{"ns":0,"exists":"","*":"Collective buying power"},{"ns":0,"exists":"","*":"Comparative effectiveness research"},{"ns":0,"exists":"","*":"Cost-benefit analyses"},{"ns":0,"exists":"","*":"David R. Henderson"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Enantiomer"},{"ns":0,"exists":"","*":"Essential medicines policies"},{"ns":0,"exists":"","*":"European Society for Medical Oncology"},{"ns":0,"exists":"","*":"Expenditure"},{"ns":0,"exists":"","*":"Formulary (pharmacy)"},{"ns":0,"exists":"","*":"Generic drug"},{"ns":0,"exists":"","*":"Government-granted monopoly"},{"ns":0,"exists":"","*":"Government Accountability Office"},{"ns":0,"exists":"","*":"Great Recession"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"JSTOR"},{"ns":0,"exists":"","*":"Jerry Brown"},{"ns":0,"exists":"","*":"Kaiser Family Foundation"},{"ns":0,"exists":"","*":"List price"},{"ns":0,"exists":"","*":"Markup (business)"},{"ns":0,"exists":"","*":"Medicaid"},{"ns":0,"exists":"","*":"Medical Expenditure Panel Survey"},{"ns":0,"exists":"","*":"Medicare (United States)"},{"ns":0,"exists":"","*":"Medicare Part D"},{"ns":0,"exists":"","*":"Medicare Part D coverage gap"},{"ns":0,"exists":"","*":"Medicare Prescription Drug, Improvement, and Modernization Act"},{"ns":0,"exists":"","*":"Memorial Sloan Kettering Cancer Center"},{"ns":0,"exists":"","*":"OECD"},{"ns":0,"exists":"","*":"OTC Markets Group"},{"ns":0,"exists":"","*":"Oncology"},{"ns":0,"exists":"","*":"Orphan drug"},{"ns":0,"exists":"","*":"Out-of-pocket expenses"},{"ns":0,"exists":"","*":"Patented Medicine Prices Review Board"},{"ns":0,"exists":"","*":"Patient Protection and Affordable Care Act"},{"ns":0,"exists":"","*":"Peter Bach"},{"ns":0,"exists":"","*":"Pharmaceutical drugs"},{"ns":0,"exists":"","*":"Pharmacy and Therapeutics"},{"ns":0,"exists":"","*":"Pharmacy benefit manager"},{"ns":0,"exists":"","*":"Prescription charges"},{"ns":0,"exists":"","*":"Prescription costs"},{"ns":0,"exists":"","*":"Prescription drug prices"},{"ns":0,"exists":"","*":"Price controls"},{"ns":0,"exists":"","*":"Price gouging"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Publicly funded health care"},{"ns":0,"exists":"","*":"Quality-adjusted life year"},{"ns":0,"exists":"","*":"Rebate (marketing)"},{"ns":0,"exists":"","*":"Retail price"},{"ns":0,"exists":"","*":"Sri Lanka National Pharmaceuticals Policy"},{"ns":0,"exists":"","*":"Stat (website)"},{"ns":0,"exists":"","*":"Think tank"},{"ns":0,"exists":"","*":"Turing Pharmaceuticals"},{"ns":0,"exists":"","*":"U.S. Customs and Border Protection"},{"ns":0,"exists":"","*":"U.S. health care reform"},{"ns":0,"exists":"","*":"US Food and Drug Administration"},{"ns":0,"exists":"","*":"United States Department of Defense"},{"ns":0,"exists":"","*":"Usual, customary and reasonable"},{"ns":0,"exists":"","*":"Valeant Pharmaceuticals"},{"ns":0,"exists":"","*":"Veterans Health Administration"},{"ns":0,"exists":"","*":"Wayback Machine"},{"ns":0,"exists":"","*":"Wholesale price"},{"ns":4,"exists":"","*":"Wikipedia:Citing sources"},{"ns":4,"exists":"","*":"Wikipedia:Manual of Style/Dates and numbers"},{"ns":4,"exists":"","*":"Wikipedia:Manual of Style/Lead section"},{"ns":4,"exists":"","*":"Wikipedia:NPOV dispute"},{"ns":4,"exists":"","*":"Wikipedia:Neutral point of view"},{"ns":4,"exists":"","*":"Wikipedia:Please clarify"},{"ns":4,"exists":"","*":"Wikipedia:Summary style"},{"ns":12,"exists":"","*":"Help:CS1 errors"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"}],"templates":[{"ns":10,"exists":"","*":"Template:Lead too short"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:As of"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:Explain"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Year"},{"ns":10,"exists":"","*":"Template:Year needed"},{"ns":10,"exists":"","*":"Template:POV section"},{"ns":10,"exists":"","*":"Template:POV"},{"ns":10,"exists":"","*":"Template:Rp"},{"ns":10,"exists":"","*":"Template:Page needed"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Webarchive"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Subscription"},{"ns":10,"exists":"","*":"Template:Subscription required"},{"ns":10,"exists":"","*":"Template:Link note"},{"ns":10,"exists":"","*":"Template:ISBN"},{"ns":10,"exists":"","*":"Template:Catalog lookup link"},{"ns":10,"exists":"","*":"Template:Trim"},{"ns":10,"exists":"","*":"Template:Yesno-no"},{"ns":10,"exists":"","*":"Template:Yesno"},{"ns":10,"exists":"","*":"Template:Error-small"},{"ns":10,"exists":"","*":"Template:Tl"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Webarchive"},{"ns":828,"exists":"","*":"Module:Webarchive/data"},{"ns":828,"exists":"","*":"Module:Check isxn"},{"ns":828,"exists":"","*":"Module:Error"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg","Wiki_letter_w.svg","Unbalanced_scales.svg"],"externallinks":["//doi.org/10.1001/jama.2016.11237","//doi.org/10.1001/jama.2015.16843","//www.worldcat.org/issn/1538-3598","//www.ncbi.nlm.nih.gov/pubmed/26619354","http://www.cmaj.ca/cgi/content/full/170/6/945?etoc","//doi.org/10.1503/cmaj.104001","//www.ncbi.nlm.nih.gov/pmc/articles/PMC359422","//www.ncbi.nlm.nih.gov/pubmed/15023915","http://www.nejm.org/doi/pdf/10.1056/NEJMp1402471","//doi.org/10.1056/nejmp1402471","http://jamanetwork.com/journals/jama/fullarticle/2545691","//www.worldcat.org/issn/0098-7484","http://www.commonwealthfund.org/publications/blog/2016/may/drug-price-control-how-some-government-programs-do-it","http://www.gao.gov/products/GAO-05-779","http://www.aarp.org/research/health/drugs/aresearch-import-869-2004-06--IB69.html","http://www.aei.org/outlook/22818","https://web.archive.org/web/20090714051407/http://www.aei.org/outlook/22818","https://www.nytimes.com/2015/12/20/opinion/sunday/no-justification-for-high-drug-prices.html","http://www.aging.senate.gov/press-releases/collins-mccaskill-open-senate-investigation-into-rx-drug-pricing-announce-intention-to-hold-hearings","http://www.baltimoresun.com/news/maryland/politics/bs-md-drug-price-gouging-20170410-story.html","https://data.oecd.org/healthres/pharmaceutical-spending.htm","https://www.cdc.gov/nchs/data/hus/2014/103.pdf","http://content.healthaffairs.org/content/31/1/208","//doi.org/10.1377/hlthaff.2011.1135","//www.worldcat.org/issn/0278-2715","//www.ncbi.nlm.nih.gov/pubmed/22232112","http://content.healthaffairs.org/content/29/5/1037","//doi.org/10.1377/hlthaff.2009.0493","//www.ncbi.nlm.nih.gov/pubmed/20338908","https://www.washingtonpost.com/archive/politics/2003/10/23/millions-of-americans-look-outside-us-for-drugs/8bfeb294-b1b2-4be5-bb4b-0764d1e899d3/","//www.worldcat.org/issn/0190-8286","http://www.cmaj.ca/content/170/6/945","//www.worldcat.org/issn/0820-3946","http://kff.org/health-costs/press-release/poll-finds-nearly-three-quarters-of-americans-say-prescription-drug-costs-are-unreasonable-and-most-blame-drug-makers-rather-than-insurers-for-the-problem/","http://linkinghub.elsevier.com/retrieve/pii/S0149291809000204","//doi.org/10.1016/j.clinthera.2009.01.006","http://linkinghub.elsevier.com/retrieve/pii/S0149291806001718","//doi.org/10.1016/j.clinthera.2006.07.009","https://medicare.com/medicare-part-d/coverage-gap-donut-hole-made-simple/","https://www.cdc.gov/nchs/data/databriefs/db184.htm","https://doi.org/10.1056/NEJMsa054436","//doi.org/10.1056/nejmsa054436","//www.worldcat.org/issn/0028-4793","//www.ncbi.nlm.nih.gov/pubmed/16738271","//www.jstor.org/stable/27804926","http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01098-3/fulltext","//doi.org/10.1016/S0140-6736(15)01098-3","//www.ncbi.nlm.nih.gov/pubmed/26638951","http://www.iphandbook.org/handbook/ch10/p09/","http://www.luc.edu/media/lucedu/law/centers/antitrust/pdfs/publications/newsviews/Ulwick%20Pay-to-Delay%20-%20Antitrust%20NewsViews%20-%20JAU%20Edits%204%2023%202015.pdf","http://www.cbsnews.com/news/higher-drug-prices-support-profits-not-research/","//doi.org/10.1001/jama.2015.18720","http://www.managedcaremag.com/archives/1009/1009.cahn_generic.html","https://www.usatoday.com/story/money/personalfinance/2014/03/03/pharmacy-benefit-managers-healthcare-costs-savings/5495317/","https://www.forbes.com/sites/matthewherper/2012/05/10/why-astrazeneca-gives-insurers-60-discounts-on-nexiums-list-price/","https://www.forbes.com/sites/matthewherper/2012/03/19/how-to-charge-1-6-million-for-a-new-drug-and-get-away-with-it/","https://blogs.wsj.com/pharmalot/2014/09/29/high-prices-for-orphan-drug-can-be-sustained-a-payer-survey-shows/","https://www.statnews.com/pharmalot/2016/03/02/fda-generic-drugs/","https://dx.doi.org/10.1186/s40545-016-0079-1","//doi.org/10.1186/s40545-016-0079-1","//www.worldcat.org/issn/2052-3211","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5034442","//www.ncbi.nlm.nih.gov/pubmed/27688886","https://www.nytimes.com/2017/04/14/business/lannett-drug-price-hike-bedrosian.html","//www.worldcat.org/issn/0362-4331","https://aspe.hhs.gov/basic-report/expanding-use-generic-drugs","https://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-on-industry-havent-fixed-delays-in-generic-drug-approvals","https://www.fda.gov/forindustry/userfees/genericdruguserfees/default.htm","http://www.cbsnews.com/news/epipen-price-hike-controversy-mylan-ceo-heather-bresch-speaks-out/","http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/UCM451179.pdf.","http://1.usa.gov/1POUpcB","https://books.google.com/books?id=-DgAe57FAGcC&pg=PA422&lpg=PA422&dq=%22united+states%22+canada+drug+development&source=bl&ots=8OG3m9xPqW&sig=OBf-c8QRoKkvXfoF6wVUiAb_K4Y&hl=en&ei=LSqhS_TQMIWglAeEk4TfDQ&sa=X&oi=book_result&ct=result&resnum=22&ved=0CFwQ6AEwFQ","https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/","http://archive.psc-cuny.org/drugprices.htm","https://books.google.com/books?id=BjKWfAz0tx4C&lpg=PA273&dq=Prescription%20Drug%20costs%20Brandon%20Kramer%20%20and%20Michael%20Shally-Jensen&pg=PA273#v=onepage&q=Prescription%20Drug%20costs%20Brandon%20Kramer%20%20and%20Michael%20Shally-Jensen&f=false","https://object.cato.org/sites/cato.org/files/serials/files/regulation/2016/4/regulation-v39n1-2.pdf","https://www.wsj.com/articles/why-the-u-s-pays-more-than-other-countries-for-drugs-1448939481","https://catalyst.nejm.org/who-has-the-power-to-cut-drug-prices/","http://www.hrsa.gov/opa/","https://www.consumerreports.org/drugs/6-tips-for-finding-the-best-prescription-drug-prices/","https://www.npr.org/sections/health-shots/2015/09/16/440612238/how-to-save-money-on-prescription-drugs-insured-or-not","http://doi.wiley.com/10.1002/phar.1802","//doi.org/10.1002/phar.1802","//www.worldcat.org/issn/1875-9114","https://jamanetwork.com/journals/jama/fullarticle/1182868","//doi.org/10.1001/jama.2012.5603","http://www.nejm.org/doi/10.1056/NEJMp1301993","//doi.org/10.1056/nejmp1301993","https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/genericdrugs/UCM167991.htm","http://journals.sagepub.com/doi/pdf/10.1177/0272989X8900900209","//doi.org/10.1177/0272989x8900900209","http://ascopubs.org/doi/10.1200/JCO.2016.68.2518","//doi.org/10.1200/JCO.2016.68.2518","//www.worldcat.org/issn/0732-183X","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5015427","//doi.org/10.1200/JCO.2015.61.6706","//www.ncbi.nlm.nih.gov/pubmed/26101248","http://academic.oup.com/annonc/article/28/10/2340/4102112/ESMOMagnitude-of-Clinical-Benefit-Scale-version-11","//doi.org/10.1093/annonc/mdx310","//www.worldcat.org/issn/0923-7534","https://academic.oup.com/annonc/article/28/11/2901/3062455","//doi.org/10.1093/annonc/mdw258","https://academic.oup.com/annonc/article/28/5/1111/2975592","//doi.org/10.1093/annonc/mdx053","http://www.aging.senate.gov/hearings/sudden-price-spikes-in-off-patent-drugs_perspectives-from-the-front-lines","https://pink.pharmamedtechbi.com/PS121171/Dems-Better-Deal-Would-Create-Drug-Price-Gouging-Enforcer","https://legiscan.com/CA/text/SB17/2017","https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=201720180SB17","//doi.org/10.1377/hlthaff.20.3.92","https://assets.aarp.org/www.aarp.org_/articles/international/proceedingsbooklet.pdf","http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9298","https://www.ncbi.nlm.nih.gov/pubmed?term=19905039%20","//doi.org/10.1007/bf03256159","//www.ncbi.nlm.nih.gov/pubmed/19905039","https://web.archive.org/web/20170608154237/http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf","http://www.aha.org/content/16/aha-drug-policy-recommendations.pdf","https://www.aarp.org/health/drugs-supplements/info-2017/rx-prescription-drug-pricing.html","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4930104","//doi.org/10.1111/jphs.12088","https://www.linkedin.com/pulse/transparency-drug-pricing-new-trend-making-ambrish-singh/","https://www.medicare.gov/find-a-plan/questions/home.aspx/","http://www.newyorker.com/magazine/2004/10/25/high-prices","https://www.fda.gov/ucm/groups/fdagov-public/documents/image/ucm129445.gif"],"sections":[{"toclevel":1,"level":"2","line":"History","number":"1","index":"1","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":810,"anchor":"History"},{"toclevel":1,"level":"2","line":"Drug expenditures","number":"2","index":"2","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":6852,"anchor":"Drug_expenditures"},{"toclevel":1,"level":"2","line":"Effects","number":"3","index":"3","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":10232,"anchor":"Effects"},{"toclevel":2,"level":"3","line":"Prescriptions from other countries","number":"3.1","index":"4","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":11064,"anchor":"Prescriptions_from_other_countries"},{"toclevel":2,"level":"3","line":"Prescription non-compliance","number":"3.2","index":"5","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":12473,"anchor":"Prescription_non-compliance"},{"toclevel":2,"level":"3","line":"Affordable Care Act","number":"3.3","index":"6","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":16092,"anchor":"Affordable_Care_Act"},{"toclevel":2,"level":"3","line":"Health Effects","number":"3.4","index":"7","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":17915,"anchor":"Health_Effects"},{"toclevel":1,"level":"2","line":"Reasons for high prices","number":"4","index":"8","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":20104,"anchor":"Reasons_for_high_prices"},{"toclevel":2,"level":"3","line":"Variability and non-transparency","number":"4.1","index":"9","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":20133,"anchor":"Variability_and_non-transparency"},{"toclevel":2,"level":"3","line":"Market exclusivity","number":"4.2","index":"10","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":21436,"anchor":"Market_exclusivity"},{"toclevel":2,"level":"3","line":"Drug company profits","number":"4.3","index":"11","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":24075,"anchor":"Drug_company_profits"},{"toclevel":2,"level":"3","line":"Pharmacy benefit managers","number":"4.4","index":"12","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":25933,"anchor":"Pharmacy_benefit_managers"},{"toclevel":2,"level":"3","line":"Drug rebates","number":"4.5","index":"13","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":27489,"anchor":"Drug_rebates"},{"toclevel":2,"level":"3","line":"Orphan drugs","number":"4.6","index":"14","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":28140,"anchor":"Orphan_drugs"},{"toclevel":2,"level":"3","line":"FDA backlog in generic drug application review","number":"4.7","index":"15","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":29088,"anchor":"FDA_backlog_in_generic_drug_application_review"},{"toclevel":2,"level":"3","line":"Research and development","number":"4.8","index":"16","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":35130,"anchor":"Research_and_development"},{"toclevel":1,"level":"2","line":"Solutions","number":"5","index":"17","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":38683,"anchor":"Solutions"},{"toclevel":2,"level":"3","line":"Discounts","number":"5.1","index":"18","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":38700,"anchor":"Discounts"},{"toclevel":2,"level":"3","line":"Drug Coupons","number":"5.2","index":"19","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":41285,"anchor":"Drug_Coupons"},{"toclevel":2,"level":"3","line":"Generics versus brand-name products","number":"5.3","index":"20","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":43476,"anchor":"Generics_versus_brand-name_products"},{"toclevel":2,"level":"3","line":"Value-based prices","number":"5.4","index":"21","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":44713,"anchor":"Value-based_prices"},{"toclevel":2,"level":"3","line":"Policy makers","number":"5.5","index":"22","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":50383,"anchor":"Policy_makers"},{"toclevel":2,"level":"3","line":"New legislation","number":"5.6","index":"23","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":52241,"anchor":"New_legislation"},{"toclevel":2,"level":"3","line":"Canada's model","number":"5.7","index":"24","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":53612,"anchor":"Canada's_model"},{"toclevel":2,"level":"3","line":"Healthcare providers","number":"5.8","index":"25","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":57149,"anchor":"Healthcare_providers"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"26","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":61489,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"27","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":61709,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"8","index":"28","fromtitle":"Prescription_drug_prices_in_the_United_States","byteoffset":61742,"anchor":"Further_reading"}],"parsewarnings":[],"displaytitle":"Prescription drug prices in the United States","iwlinks":[],"properties":[{"name":"defaultsort","*":"Prescription Drug Prices In The United States"},{"name":"wikibase_item","*":"Q7240898"}]}}